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EVALUATION OF NON-INVASIVE IMAGING METHODS FOR 
QUANTIFICATION OF TREATMENT RESPONSE 
by 
Benjamin A. Hoff 
Chair: Craig J. Galbán 
 
Therapeutic response assessment of cancer has long been facilitated by non-invasive imaging methods 
such as magnetic resonance imaging (MRI) and x-ray computed tomography (CT) in the clinic. Standards 
of patient care are designed around the most common cases, which may not always be efficacious. 
However, through evidence-based medicine there has begun a shift toward more individualized care. 
Standard clinical practice for cancer response assessment utilizes only volumetric change, measured prior 
and following the completion of therapy, providing no opportunity to adjust the treatment. In addition, 
novel targeted therapies, which may not result in a substantial decrease in tumor volume, are becoming 
more prevalent in the treatment of tumors. There is a clear need for non-invasive biomarkers that provide 
near real-time information on the anatomical and physiological makeup of the tumor post-treatment 
initiation. Tools for assessing early treatment response may allow physicians to dynamically optimize 
treatments individually, enhancing patient prognoses and avoiding unnecessary patient morbidity. In the 
following studies, I have evaluated various non-invasive imaging tools for early detection of treatment 
response in rodent models of disease. Tissue apparent diffusion coefficients (ADC) are known to correlate 
well with cellular status in cancer, and have shown promise in the detection of early tumor treatment 
response. Several different numerical models of higher-order diffusion signal attenuation were evaluated 
to determine their sensitivity to treatment response compared to the standard diffusion model. Dynamic 
contrast-enhanced (DCE-) MRI has shown sensitivity to vascular changes in cancer and was evaluated as 
an imaging biomarker of treatment response using a novel vascular-targeted therapy. Quantitative indices 
generated from DCE-MRI data were compared to diffusion (ADC) and volumetric MRI readouts for 
response assessment. The utility of imaging readouts from concurrent MRI, CT, bioluminescence, and 
fluorescence imaging was also evaluated in a model of bone metastasis. Further, a new voxel-based 
analytical technique, the parametric response map (PRM), was applied to CT images of metastatic bone 
disease and osteoporosis to evaluate bone response to treatment and hormone deprivation, respectively. 
Use of these tools may help improve the clinical effectiveness of cancer patient therapy as well as drug 




 Introduction Chapter 0:
Diagnosis and assessment of therapeutic response in cancer has long been facilitated by 
non-invasive imaging methods such as magnetic resonance imaging (MRI), x-ray radiographs, 
positron emission tomography (PET), single photon emission computed tomography (SPECT) 
and x-ray computed tomography (CT) in the clinic and more recently optical imaging 
(fluorescence and bioluminescence) for pre-clinical models. On the subject of tumor biology 
there is still much that is not understood, for example some patients given a therapy may exhibit 
a positive outcome while others with the same therapy and clinical histopathological 
characteristics may not. Because of this, evaluation of the effectiveness of a therapy is valuable 
in determining a patient’s treatment strategy and prognosis. Traditional evaluation of cancer 
treatment efficacy has relied heavily on volumetric monitoring of tumor burden, with decreases 
indicating a successful response. These changes, however, may not be detectable until well after 
the treatment regime has been completed, precluding adjustment of the treatment strategy based 
on its efficacy. Development of tools for assessing early treatment response may allow 
physicians to dynamically optimize treatments on an individual level, enhancing patient 
prognoses and avoiding unnecessary patient morbidity. 
Diffusion-MRI is an MRI sequence capable of quantifying the molecular motion of 
protons primarily in water using bipolar motion-sensitive gradients. The magnitude of diffusion 
weighting is measured in b-values, which are a function of gradient strength, duration and 
spacing between gradients. Diffusion weighting can be applied directionally, allowing some 
assessment of the tissue structures as in diffusion tensor imaging (DTI), or isotropically, 
resulting in a general assessment of tissue water diffusion. In the simplest case only two 
diffusion-weighted images at a low and nominal b-value (~0 and ~1000 s/mm
2
, respectively) are 
required to generate the quantitative metric, the apparent diffusion coefficient (ADC) map, 
assuming mono-exponential decay in the MRI signal with increasing b-value. ADC has been 
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shown to be indicative of cellular status in cancer treatment [1-12]. Increases in ADC have 
correlated well with tumor cell death caused by cytotoxic therapies and are well-documented for 
nominal diffusion weighting. Recent studies, however, have shown that at high diffusion 
weighting (b-value) the signal attenuation curve deviates from a true mono-exponential behavior 
[9, 13-21]. Although no single theory has yet been embraced, the most popular models either use 
the sum of two diffusion populations (proposed as intra- and extra-cellular water) or a spectrum 
of diffusion rates attributed to the continuum of water hydration shells surrounding biological 
structures. Changes in these non-mono-exponential metrics may prove sensitive for detecting 
treatment response. 
Dynamic contrast-enhanced- (DCE-) MRI is a technique using small-molecule 
paramagnetic contrast-enhancing tracers injected intravenously to extract tissue vascular 
properties from time-course T1-weighted MR images. Contrast enhancement of the T1-weighted 
signal is proportional to the voxel concentration of contrast agent, allowing the extraction of 
pharmacokinetic tissue properties through modeling. Growing interest has been apparent in 
targeted cancer therapies, one focus of which is anti-vascular drugs such as Bevacizumab and 
Aflibercept. These targeted agents inhibit cellular signaling and resulting angiogenesis, the 
growth and recruitment of blood vessels, within the tumor. DCE-MRI has been shown to detect a 
reduction in vascular leakiness and blood volume within a treated tumor. In the following, both 
DCE- and DW-MRI were used to evaluate treatment response in a 9L rat gliosarcoma model 
treated with the new therapeutic agent, Aflibercept. A few different widely-used analytical 
models were also compared on the same data to assess variation of response sensitivity in these 
models. 
For the development and evaluation of new cancer pharmaceuticals, non-invasive 
imaging biomarkers have proven very useful in reducing total necessary animal populations as 
well as expediting the measurement of a therapeutic response. Quantification of treatment 
response in bone metastases has proven to be an elusive task, with currently no clinically-
accepted criteria. Recent studies have shown a critical link between metastatic cancer and its 
micro-environment, coined the “seed and soil” [22]. Through interaction with bone, certain 
cancer phenotypes are spurred to grow and proliferate, resulting in a vicious cycle of bone 
remodeling and tumor growth. With the wide variety of available imaging modalities, a great 
deal of physiological information can now be obtained from a single subject longitudinally over 
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the course of the study. With the combination of imaging modalities, researchers are now able to 
quantify multiple treatment responses at essentially the same time as well as longitudinally, in 
this case both bone and tumor response. In the following, an animal model of boney metastasis is 
presented, and treatment response is evaluated by DW-MRI, quantitative CT, bioluminescence 
(BLI), and fluorescence (FLI) imaging after treatment with the bisphosphonate, zoledronic acid, 
or the cytotoxic agent, docetaxel. These two therapies serve to highlight the two extreme 
treatment cases: anti-tumor-environment or anti-tumor, respectively, and are both clinically 
relevant therapies. Using multiple readouts, a more comprehensive perspective for new drug 
evaluation and efficacy screening can be achieved. 
Traditionally, quantitative cancer imaging has been evaluated using whole-tumor 
statistics such as the mean or histogram-based analyses. A new voxel-wise approach to detecting 
treatment response, the function diffusion map (fDM), has successfully been applied to DW-
MRI, resulting in increased sensitivity to localized diffusion changes over mean volume statistics 
[23-28]. This technique uses spatially aligned serial images to compare diffusion images both 
spatially and temporally. This same technique, now termed the parametric response map (PRM), 
has already been expanded to other images, including DCE- and dynamic susceptibility contrast 
(DSC-) MRI. In the following, this PRM analysis will be applied to bone CT images (in 
Hounsfield units, HU) to evaluate localized bone changes both in animal models and clinical 
metastatic cancer patients. Sensitivity of PRMHU to bone changes was validated through a well-
establish ovariectomy-induced osteoporosis model in rats, and further characterized in both 
osteolytic and osteoblastic models of bone metastasis in mice. 
In conclusion, there exists a great variety of quantitative imaging options for the 
assessment of cancer treatment response, particularly in pre-clinical imaging where tissue depths 
are not enough to inhibit optical imaging modalities. Through early detection of treatment 
response clinical patient treatments may be individualized, allowing the option to adjust 
treatments virtually “on the fly”. In addition, through the use of a multimodal quantitative 
imaging approach, tailored to a focused treatment or effect, a more comprehensive and efficient 
evaluation of mixed treatment effects can be possible. Even for a single imaging modality, for 
example DCE-MRI, it is important to understand the accuracy and limitations of the model to be 
used in order to extract valid conclusions from the results. In the following chapters various 
analytical models for multi-exponential diffusion MRI and DCE-MRI are evaluated for both 
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sensitivity to physiological or model parameter change and sensitivity to noise in the images. 
The use of a multi-modality imaging strategy is also evaluated, using MRI, x-ray CT, 
bioluminescence, and fluorescence imaging, for a more comprehensive evaluation of 
tumor/stroma treatment response using a limited study population. Finally, a new method for 
evaluating spatially-localized changes in 3D images is evaluated on CT images of the bone. This 
method may see its greatest use for evaluation of bone metastases, which currently have no 
official criteria for assessing treatment response in the clinic. This manuscript provides an 
evaluation of several methods for quantifying physiological changes in vivo.  
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 Non-Mono-exponential Diffusion Chapter 1:
1.1: Chemotherapeutic Treatment Response 
Included with permission from John Wiley and Sons: 
Hoff BA, Chenevert TL, Bhojani MS, Kwee TC, Rehemtulla A, Le Bihan D, Ross BD, Galbán CJ. 
Assessment of multiexponential diffusion features as MRI cancer therapy response metrics. Magn Reson 
Med. 2010 Nov;64(5):1499-509. 
1.1.1:  Introduction 
Diffusion-weighted magnetic resonance imaging (DWI) shows promise as an imaging 
biomarker for treatment response in glioma patients [1-9] as well as in a variety of other clinical 
tumor types [10-16]. Routine in almost all preclinical and clinical scanners, diffusion maps can 
be generated from a minimum of two images acquired at low (b-value ~ 100 sec/mm
2
) and high 
(b-value ~ 1000 sec/mm
2
) diffusion weightings. Assuming mono-exponential signal attenuation 
with b-value, the apparent diffusion coefficient (ADC) can be calculated analytically. The 
application of diffusion MRI for the detection of early tumor treatment response was first 
reported using a rodent glioma model using diffusion weightings at nominal b-values ( 1000 
sec/mm
2
) [17]. This initial report has been verified and expanded by ensuing publications using 
different tumor models and therapeutic agents [1, 18, 19], supporting the use of diffusion MRI as 
a sensitive imaging biomarker capable of detecting early cellular changes in treated tumors 
which precede macroscopic volumetric response. 
The efficacy of this technique lies in its sensitivity to the molecular motion of water, 
which is affected by cellular, subcellular, and macromolecular elements that impede otherwise 
free diffusion of water. Thus, therapeutic changes within the tumor at the cellular level can be 
monitored by serial diffusion measurements [20-23]. Through thermal random motion, water 
molecules sample the surrounding microarchitecture within tissues at length scales (few microns) 
much smaller than typical MRI voxel resolution (~millimeter). The theoretical basis for diffusion 
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analysis is that cell membranes and other structures hinder the diffusion of molecules [20, 24]. 
The magnitude of diffusion-driven displacement is altered by tortuosity and hindering effects and 
can therefore be used to infer their presence and density. Studies have revealed that in biological 
systems water proton signal attenuation due to diffusion weighting does not follow mono-
exponential decay, and the deviation from mono-exponential behavior is best observed at 
relatively high b-values ( 3000 sec/mm
2
). A more accurate description of signal attenuation 
with b-value over this wide b-value range requires more complex biophysical models [25-28]. 
An early interpretation of multiexponential diffusion patterns was that water moves 
within two or more compartments representing pools of “fast” (extracellular) and “slow” 
(intracellular) diffusion components in the signal. At low b-values the “fast” diffusion pool 
dominates signal attenuation, whereas at high b-values the “slow” diffusion pool dominates 
leading to a biexponential form for signal decay. Biexponential signal attenuation in DWI has 
been studied extensively in a variety of biological systems, and the physical mechanisms that 
govern nonmonoexponential decay continue to be an area of debate. An alternative formalism for 
the nonmonoexponential decay incorporates the underlying complexity in the diffusion medium 
as a continuous distribution of diffusion coefficients arising from a multiplicity of pools. Termed 
the “stretched-exponential” formalism, Bennett et al. [29] provided an analytical representation 
of the signal attenuation as a function of the probability density with a particular diffusion 
coefficient. Although this formalism can be used to infer the intravoxel diffusion heterogeneity 
within a biological system, it does not lend itself to straightforward association between 
biophysical compartments and signal decay. Although the “stretched-exponential” formalism has 
not been evaluated for its sensitivity to treatment response in tumors, this method has shown 
promise for characterizing tumors in brain cancer patients [30, 31]. 
Research investigating the sensitivity of high b-value DWI for treatment assessment has 
shown promising results [6, 32]. Mardor et al. have demonstrated in patients with malignant 
brain lesions that the ratio of the diffusion coefficient from the ‘‘fast’’ pool and the “slow” pool 
signal fraction is highly sensitive to radiation-induced changes in the tumor. This parameter not 
only demonstrated a significant change from baseline as early as 1 week post-treatment initiation 
but was capable of predicting clinical outcome in all of the studied patients [6]. In contrast, 





, respectively) was found to be predictive of outcome in only half of the patient 
population studied. Sensitivity of high b-value DWI to treatment was also observed in a colon 
cancer mouse model [32]. These authors used the area under the normalized 
nonmonoexponential diffusion curve to quantify the diffusion characteristics of the tissue. This 
diffusion index was found to provide early prognostic information on animal responsiveness to 
treatment. 
In this study, three nonmonoexponential diffusion formalisms applied over an extended 
range of b-values (120–4000 sec/mm
2
) were tested against the conventional two-point ADC 
measurement to determine their sensitivity to therapy-induced changes of tissue using a rodent 
brain tumor model. Results showed similar time response curves for all diffusion indices 
following treatment. Although the highest fractional change following treatment was observed 
using the biexponential formalism, these results were not significantly different from those 
observed using the conventional two-point ADC calculation. 
1.1.2: Methods 
Animal Tumor Models 
9L gliosarcoma cells were obtained from the Brain Tumor Research Center at the 
University of California in San Francisco. The cells were grown as monolayers in 10 cm
2
 sterile 
plastic flasks in DMEM with 10% fetal bovine serum, 100 IU/mL penicillin, 100 mg/mL 
streptomycin, and 2 mM L-glutamine in an incubator held at 37C and 95%/5% air/CO2 
atmosphere. Before implantation, cells were harvested by trypsinization, counted, and re-
suspended in serum-free medium for injection.  
Tumor implantation was performed on Male Fischer 344 rats (Harlan Sprague-Dawley, 
Indianapolis, IN), weighing ~125–150 g, as previously described [33]. Briefly, animals were 
anesthetized with a ketamine/xylazine mixture (87/13 mg/kg) administered intraperitoneal. A 
small incision was then made over the right hemisphere of the cranium. A 1 mm diameter burr 
hole was drilled through the skull using a high-speed surgical drill, and a 5 mL suspension 
containing 1 x 10
5
 9L cells was injected through the burr hole to a depth of 3 mm. After injection 
of the cells, the burr hole was filled with bone wax to prevent extra-cranial extension of the 
tumor, and the surgical area was cleaned using 70% ethanol. Vetbond (3M, St. Paul, MN) was 




Once the tumors reached 40–80 mm
3
 as quantified using T2-weighted MRI, pretreatment 
diffusion-weighted (DW) images (details below) were acquired for all animals. At the time of 
treatment, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) (LKT Laboratories, St. Paul, MN) was 
freshly prepared and formulated to a final concentration of 5 mg/mL BCNU in 10% ethanol. 
Subsequent to their pretreatment DWI scan, animals either received a single bolus intraperitoneal 
injection of BCNU (9.98 mg/kg; n = 13) or 10% ethanol as the control vehicle (n = 10). 
Typically, tumors increased in volume by 400% over the duration of the study (2 weeks post-
treatment initiation), and euthanasia was accomplished by CO2 overdose. 
MRI Scans 
During MRI examinations, animals were anesthetized with 1–2% isoflurane/air, and body 
temperature was maintained by blowing warm air through the bore of the magnet using an Air-
Therm (World Precision Instruments, Sarasota, FL). MR scans were performed immediately 
before treatment and every 3 days thereafter using a 9.4 T, 16 cm horizontal bore Varian (Palo 
Alto, CA) Direct Drive system with a quadrature rat head coil (Doty Scientific, Inc., Columbia, 
SC). DW images were acquired using a spin-echo sequence, with a navigator echo and gradient 
waveforms sensitive to isotropic diffusion [34], with the following parameters: repetition time 
(TR)/echo time (TE) = 4000/41 ms, field of view (FOV) = 30 mm, matrix size = 64 x 64, slice 
thickness = 2 mm, number of slices = 8, sweep width = 50 kHz, gradient pulse width = 10.5 ms, 
gradient pulse separation = 25 ms, and b-values (x-gradient, y-gradient, and z-gradient 
amplitudes) of 120 (5.3, 4.8, and 4.2 G/cm), 1200 (16.6, 15.0, and 13.1 G/cm), 1600 (19.1, 17.3, 
and 15.6 G/cm), 2000 (21.3, 19.2, and 17.4 G/cm), 3000 (25.9, 23.4, and 21.3 G/cm), and 4000 
sec/mm
2
 (29.7, 26.9, and 24.6 G/cm) with averages of 1, 1, 1, 1, 4, and 16, respectively. DWI 
scans were constrained to a total scan time of 2 h based upon an institutionally approved animal 
protocol. In addition to the time constraint, only voxels in the tumor with a signal to noise (SNR) 
> 6 at high diffusion weighting (i.e., b = 4000 sec/mm
2
) were evaluated. The first step in 
maintaining this constraint was to determine a voxel size that provides adequate SNR and 
resolution within a 2 h MR experiment. As observed in Chenevert et al. [3], 9L rodent brain 














 range, was used to determine sequence parameters (i.e., FOV, slice thickness, 
and averages) that provide a SNR > 6 at b = 4000 sec/mm
2
 [35].  
Post-processing of Diffusion-Weighted Images 
All MRI data were transferred to a PC, interpolated to a matrix size of 256 x 256, and 
analyzed using in-house software developed in MATLAB (The MathWorks, Inc., Natick, MA). 
Curve-fitting was performed using an un-weighted non-linear least-squares algorithm using an 
initial parameter guess based on literature values. Diffusion signal decay, found to follow a 
nonmonoexponential trend in healthy brain tissue and tumor from our animal model, was 
analyzed using three diffusion approaches. 
Two-Point Analytical Formalism 
The simplest of all three techniques investigated captures the nonmonoexponential trends 
observed in the DW images from a two-point subsampling of the signal decay curve using the 
following equation: 
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where S1 and S2 are the signal intensities at b-values b1 and b2, respectively, and ADC1–2 is the 
diffusion coefficient obtained using b1 and b2. The conventional mono-exponential ADC was 
calculated using b-values of 120 and 1200 sec/mm
2
 (ADC120–1200), which captures the rapid 
diffusion decay in the nominal-b regime while avoiding perfusion effects observed at very low b-
value (<100 sec/mm
2
). Slow diffusion decay, observed in the high-b regime, was captured by 
determining the ADC using b-values of 2000 and 4000 sec/mm
2
 (ADC2000–4000). The ratio of 
ADC2000–4000/ADC120–1200, defined as RTP, was used as an empiric index of nonmonoexponential 
behavior derived from the piece-wise two-point formalism. An RTP close to one implies mono-
exponential behavior, whereas a decreasing RTP implies greater disparity in signal decay between 
low-b and high-b regimes, thus greater multiexponential behavior. 
Stretched Exponential Formalism 
This formalism defines the divergence of a diffusible particle from mono-exponential 
trends as anomalous diffusion (29,36). Referred to as the stretched exponential, this formalism 
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where S is the signal intensity at a given b-value, S0 is the signal intensity with no diffusion 
weighting, DDC is the distributed diffusion coefficient, and  is the anomalous exponent bound 
between 0 and 1 [29, 36]. By inspection of Eq. 2, it should be clear that α = 1 is equivalent to 
monoexponential diffusion signal decay. Conversely, an  approaching 0 indicates a high degree 
of multiexponential signal decay, thus  will be used as the nonmonoexponential index derived 
from the stretched exponential formalism. This convention maintains consistency with Bennett et 
al.’s [29] definition of a as a diffusion heterogeneity index, although we remind the reader that a 
numerically high a value (~1) represents a low intravoxel diffusion heterogeneity approaching 
monoexponential decay, whereas a numerically low a value represents a high degree of diffusion 
heterogeneity exhibited as multiexponential decay. It is also worth emphasis that the term 
“heterogeneity” in this context refers to intravoxel heterogeneity of exponential decays, as 
opposed to intervoxel heterogeneity of diffusion coefficients as often is the case, particularly in 
tumor. Parameter maps of DDC and  were calculated by linearizing the stretched exponential 
equation and then fitting it to the DW images in a pixel-wise manner over all b-values using a 
linear least-squares technique. 
Biexponential Model 
Calculation of the biexponential diffusion components was performed by a pixel-wise fit 
to all DW images of the following equation: 
  ( )    (   
        
    ), [1.1.3] 
where S and S0 are signal intensities at a given b-value and no diffusion weighting, respectively, 
D1 and D2 are the fast and slow diffusion coefficients, respectively, and V1 and V2 are the fast 
and slow signal fraction contributions, respectively. The fractional signal components are related 
by the expression V2 = 1 – V1. The fit was performed using a nonlinear least-squares technique. 
Image Analysis 
Volumes of interest (VOI) over the tumors were manually contoured on the low b-value 
DWI, which exhibits T2-weighted contrast and serves for quantification of tumor volume. Low 
SNR voxels were excluded before calculation of mean parameter values within the VOI from 
each diffusion formalism. To accomplish this, voxels having SNR  6 on the b = 4000 sec/mm
2
 
DWI were identified by software in a binary 3D mask. The mask was then applied to all DW 
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images guaranteeing that only those voxels with a SNR > 6 were evaluated. Regions of necrosis 
or blood pools, typically observed as hypo-intense on T2-weighted images, were manually 
omitted from the VOIs. Parameter change with respect to treatment was assessed using the 
percent change of the mean of each parameter (100x [PostTherapy – PreTherapy] / PreTherapy). 
Histology 
An additional six animals were used for obtaining histology of the tumors for control (n = 
3) and treated animals (n = 3) 6 days post-treatment. 9L tumors from these animals were placed 
in buffered formalin overnight, dehydrated in 70% ethanol, and subsequently embedded in 
paraffin. Tissue sections were prepared for histological processing by routine techniques. Briefly, 
paraffin sections (5 mm thick) were cut on a microtome and heated for 20 min at 65C. Slides 
were deparaffinized in xylene with three changes for 5 min each and then rehydrated through an 
alcohol gradient for 2 min each (100% alcohol, 95% alcohol, and 70% alcohol). Sections were 
first stained using a Gill’s 2x hematoxylin solution and then subsequently stained with eosin. 
Statistics 
A paired Student’s t-test was used to assess significance between the percent changes in 
each parameter post-treatment initiation from pretreatment values and between the percent 
change in similar parameters for each formalism at individual time points in the treated group. 
Group comparisons were assessed for each parameter at individual time points using an 
independent sample Student’s t-test. Treatment efficacy on overall survival was assessed by log-
rank test and displayed using a Kaplan-Meier survival curves. All statistical computations were 
performed with a statistical software package (SPSS Software Products, Chicago, IL). Statistical 
significance was assessed at P < 0.05.  
1.1.3: Results 
Representative DW images, acquired at b-values of 120, 1200, 3000, and 4000 sec/mm
2
, 
are demonstrated in Figure 1.1.1. Using low b-value images, delineation of tumor extent allowed 
for tumor volumes to be measured over time. Although the tumor volume in treated animals did 
appear to have a slower rate of growth than controls, this did not result in statistical differences 
in tumor volume between groups at individual time points (Figure 1.1.2a). Nevertheless, as 
presented in Figure 1.1.2b, the median survival of treated animals (9 days with a 95% confidence 
interval of 8.2–9.8 days) was found to be significantly longer than control animals (5 days with a 
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95% confidence interval of 3.8–6.2 days; P = 0.001). Increased longevity in treated animals was 
consequent to tumor cell death, which was verified by histology. Histological sections of 
representative control and treated animals at day 6 post-treatment initiation are presented in 
Figure 1.1.3. Following BCNU treatment, fewer nuclei were observed in the treated tumor than 
control, suggesting massive cell kill in the tumor volume of treated animals. An increase in 
pleomorphism and giant cells was also evident in the treated tumors. Tumor growth rate kinetics 
and histology were consistent with previous findings using the 9L gliosarcoma rat brain tumor 
model [6]. 
 
Figure 1.1.1 Representative diffusion-weighted images of a rat brain harboring a 9L 
gliosarcoma acquired at b-values of (a) 120, (b) 1200, (c) 2000, and (d) 4000 sec/mm
2
. Images 
were independently scaled for better visualization at higher b-values. 
 
Presented in Table 1.1 is a summary of the parametric indices generated from the three 
formalisms for control and treated tumor groups acquired at baseline. Significant differences in 
indices with similar diffusion properties were observed between all formalisms. In contrast, 
group comparisons did not result in statistical differences for any given parameter. To verify the 
accuracy of our biexponential fit to the data, pretreatment values were calculated in healthy rat 




/sec and 0.79) were found to be 











/sec, which could be a result 




 as opposed to the 4000 s/mm
2
 used here. 
 
Figure 1.1.2: (a): Plot over time of the mean tumor volume. Data presented as mean ± 
SEM. Significant difference in mean tumor volume between groups was assessed using an 
unpaired Student’s t-test. P values are provided at individual time points. (b): Kaplan-Meier 
survival plot for overall survival is presented for control and treated animals. Controls are shown 
as solid line with diamond markers and treated are shown as dashed lines with square markers. 
Significant differences in overall survival were observed between groups as assessed using a log-
rank test (P = 0.001). 
 
Table 1.1: Mean Parameter Values at Baseline. Pre-treatment data are presented for 





Figure 1.1.3: Hematoxylin–eosin-stained sections of intracerebral 9L tumors for 
representative (a) control and (b) BCNU-treated animals on day 6 post-treatment. 
 
As shown in Figure 1.1.4, maps of parameters more sensitive to “fast diffusion” 
properties pretreatment (left column) and 6 days following BCNU treatment (right column) were 
generated over the tumor volume and superimposed on T2-weighted images. Top-row images 
(Figure 1.1.4a,d) represent ADC120–1200, middle-row images (Figure 1.1.4b,e) are DDC, and 
bottom-row images (Figure 1.1.4c,f) are D1. In addition, the full time course of ADC120–1200, 
DDC, and D1 expressed as percent change from pretreatment values are illustrated in Figure 
1.1.4g–i, respectively. D1 was found to be significantly larger than ADC120–1200 and DDC at 
baseline (Table 1.1) and at day 6 post-treatment initiation as well as having, in absolute terms, a 




/sec) within the tumor volume allowing easier 
visualization of tumor features (Figure 1.1.4c,f). As for the responsiveness of these indices to 
treatment, the percent change from baseline peaked at day 6 post-treatment initiation, followed 
by a descent toward baseline at day 9 (Figure 1.1.4g–i). Near identical trends were observed for 
ADC120–1200 and DDC with significant group and baseline value differences observed on days 3 
and 6. Similar results were observed for D1 except for the negligible group differences at day 3 
post-treatment-initiation, which is attributed to the slower rate of ascent from baseline (Figure 
1.1.4i). Although change in D1 was found to be most responsive to treatment with a ~25% 
increase at day 6 from baseline, it was not found to be significantly larger at this time point or 
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any other time point from what was observed for change in ADC120–1200 and DDC (P = 0.204 and 
P = 0.711, respectively, for day 6). 
 
 
Figure 1.1.4: Representative maps and line plots of percent change in parameters 
sensitive to ‘‘fast diffusion’’ generated using (a, d, g) twopoint, (b, e, h) stretched-exponential, 
and (c, f, i) biexponential formalisms are provided. Diffusion maps, overlaid on T2-weighted 
images of a rat brain, were acquired at days 0 (a, b, c) and 6 (d, e, f) post-treatment initiation. 
Line plots (g, h, i) consist of mean values and standard errors from control and treated groups 
over the entire experiment. Data are presented as the mean ± the standard error of the mean. The 
symbols † and * designate significant differences from baseline and between groups, 
respectively. Statistical significance was assessed at P < 0.05. 
  
Analogous parametric maps and line plots to Figure 1.1.4 are illustrated in Figure 1.1.5 
for quantities sensitive to the “slow diffusion” component of the decay curve, namely ADC2000–
4000 (Figure 1.1.5a,c,e) and D2 (Figure 1.1.5b,d,f). In general, ADC2000–4000 and D2 showed little 
change in day 6 values from baseline (Figure 1.1.5a–d). Percent change in the mean values over 
time corroborates observations found in the maps from the representative animal (Figure 1.1.5a–
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d) with ADC2000–4000 and D2 peaking at less than 10% of baseline. Group differences were only 
observed at day 3 for D2, partly attributed to a drop in control D2. Interestingly, both ADC2000–
4000 and D2 resulted in ~7% decrease from baseline on day 9 post-treatment initiation (Figure 
1.1.5h,i), which correlated with the descent back to pretreatment values observed in diffusion 
coefficients sensitive to “fast diffusion” (Figure 1.1.4).  
 
 
Figure 1.1.5: Representative maps of the ‘‘slow diffusion’’ coefficients and line plots of 
percentage change in parameters generated using (a, c, e) two-point and (b, d, f) biexponential 
formalisms are provided. Diffusion maps, overlaid on T2-weighted images of a rat brain, were 
acquired at days 0 (a, b) and 6 (c, d) post-treatment initiation. Line plots (e, f) consist of mean 
values and standard errors from control and treated groups over the entire experiment. Data are 
presented as the mean ± the standard error of the mean. The symbols † and * designate 
significant differences from baseline and between groups, respectively. Statistical significance 





Figure 1.1.6: Representative nonmonoexponential metric maps and line plots of 
percentage change in parameters generated using (a, d, g) two-point, (b, e, h) stretched-
exponential, and (c, f, i) biexponential formalisms are provided. Metric maps, overlaid on T2-
weighted images of a rat brain, were acquired at days 0 (a, b, c) and 6 (d, e, f) post-treatment 
initiation. Line plots (g, h, i) consist of mean values and standard errors from control and treated 
groups over the entire experiment. Data are presented as the mean ± the standard error of the 
mean. The symbols † and * designate significant differences from baseline and between groups, 
respectively. Statistical significance was assessed at P < 0.05. 
 
As discussed previously, a comparison of the absolute numerical value of 
nonmonoexponential metrics is not meaningful because of differences in how these parameters 
are defined. Qualitatively, RTP was most sensitive to treatment exhibiting the largest percent drop 
from baseline values (Figure 1.1.6). The remaining parameters showed similar qualitative trends 
from baseline to day 6 post-treatment-initiation. A significant drop from pretreatment values was 
observed at day 6 for RTP (11%),  (7%), and V2 (6%). RTP and  continued to have 
significantly lower values to baseline at day 9, which was not established by V2 because of 
scatter in the data. Group differences were only found at day 6 for RTP and . The ratio of D2 and 
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D1, as obtained from the biexponential formalism, provided analogous results to RTP (data not 
shown). Although the mean value of D2/D1 decreased by more than 15%, these results were not 
found to be statistically different from the controls. 
1.1.4: Discussion 
DW MRI has shown potential as a surrogate biomarker for treatment response in cancer 
patients [37-40]. Acquisition of diffusion maps is typically performed at relatively moderate 
diffusion weighting, i.e., b-values that typically span the 0–1000 sec/mm
2
 range. It is speculated 
that water diffusion measurements at higher b-values may provide increased sensitivity to 
relevant drug-induced changes in tumor composition by virtue of possible therapeutic alteration 
of cellular constituents responsible for the “slow diffusion” components of signal decay observed 
at relatively high b-values. This study sought to determine the sensitivity of diffusion parameters 
derived from various mathematical formalisms of nonmonoexponential water diffusion to 
treatment-induced tissue alteration following treatment of the 9L glioma model. 
Previous work by our group using the 9L brain tumor model has shown that ADC 
calculated using moderate b-values can increase by up to 60% within a week following a single 
dose (13.3 mg/kg) of BCNU (3). As measured in this study, parameters sensitive to “fast 
diffusion” showed similar trends following a single bolus (9.98 mg/kg) of BCNU, all peaking by 
day 6 post-treatment-initiation. The maximum percent change in parameter value from baseline 
was observed in D1. This is expected because D1 is a more specific measurement of “fast 
diffusion” than DDC and ADC120–1200, which are not completely devoid of the “slow diffusion” 
properties in the signal decay curve. A positive therapeutic effect was confirmed by an increased 
overall survival (Figure 1.1.2) as well as direct evidence from histological tumor sections 
comparing treated versus untreated tumors (Figure 1.1.3). Another characteristic trend of ADC 
following treatment, which has been observed here and by others, is the temporally evolving 
descent to baseline values. This has been found to correlate with tumor cell repopulation, which 
has been reported in the literature [28]. In contrast, those indices specifically sensitive to “slow 
diffusion” exhibited a negligible change post-treatment initiation until day 9 where a drop had 
occurred in both parameter values when compared with baseline. The lack of response following 
treatment and the sudden drop in ADC2000–4000 and D2 during cell repopulation, which is reflected 
in the diffusion coefficients sensitive to “fast diffusion” descent to baseline, is quite perplexing, 
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suggesting independent mechanisms affecting the “fast” and “slow” diffusion properties of the 
tissue. Additional mechanisms, such as macrophage infiltration and clearance of 
macromolecules, may also contribute to our observations. Despite subtle variations in the trends 
of the parameters with either “fast” or “slow” diffusion properties, there was no significant 
difference in the percent change from baseline between diffusion parameters with like properties. 
As opposed to the diffusion coefficients, the nonmonoexponential metrics, RTP, , and 
V2, are defined differently and thus cannot have the same interpretation, even though they have 
similar trends. Consequent to the negligible change in ADC2000–4000, RTP is driven almost 
exclusively by ADC120–1200 for most of the study. Not until day 9, did we see a divergence from 
this dependence, which is partly attributed to the mirrored descent observed in ADC2000–4000 to 
ADC120–1200 resulting in a negligible change in RTP from day 6 to day 9 post-treatment initiation. 
Analogous but not significant results were observed for D2/D1. Large variability in the 
measurements of D1 and D2 (Figs. 4 and 5) from the nonlinear fit most likely contributed to the 
non-statistical difference in D2/D1 between groups. In contrast, the slow diffusion signal fraction, 
V2, defines the proportion of water signal in the slow compartment independent of water 
diffusivity. The drop in V2 suggests shrinkage of the slow compartment volume fraction, 
conversely an expansion of the fast compartment volume fraction, following treatment initiation. 
The anomalous exponent  represents the deviation of signal attenuation from mono-exponential 
behavior ( = 1). This perturbation is assumed to be attributed to increased heterogeneity within 
the tissue. The decrease in  seen in Figure 1.1.6h suggests an increase in tumor intravoxel 
heterogeneity that maximizes at day 6 and continues to day 9. Following treatment of the tumor 
with BCNU, a loss in tumor cellularity (Figure 1.1.3) pushed the attenuation curve further from 
monoexponential behavior than what was observed from control and baseline values (Table 1.1). 
Because of similar trends in the nonmonoexponential metrics and the lack of response to 
treatment of the “slow diffusion” indices, one may speculate that the “fast diffusion” properties 
within the tumor dominate what we observe for RTP, , and V2 following treatment. Various 
theories have been proposed to provide a physical account of the deviation in diffusion-sensitive 
signal attenuation from monoexponential behavior in biological tissue [20, 21, 41]. Use of these 
theories to determine the exact physical properties that govern nonmonoexponential water 
diffusion warrants further investigation but is beyond the scope of this study. 
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Irrespective of the mechanisms driving nonmonoexponential behavior in diffusion-
sensitive signal attenuation, high b-value DWI provides additional advantages over conventional 
mono-exponential ADC measurements that may provide a more sensitive biomarker for tumor 
treatment response and characterization. The conventional approach for measuring ADC, b-
values around 1000 sec/mm
2
, is hindered by the presence of highly diffuse tissue, such as cysts 
and necrotic areas, which may reside within or around the tumor volume adding increasing 
difficulty in localizing viable tumor. At higher b-values, these rapidly diffusing regions within 
tumors are essentially filtered out leaving only densely packed tumor that has lower ADC values. 
Recent research investigating the sensitivity of high b-value DWI for treatment assessment has 
shown promising results. Mardor et al. have demonstrated in patients with malignant brain 
lesions that the ratio of D1 and V2 [defined as R in Eq. 1 [6]] is highly sensitive to radiation-
induced changes in the tumor. This parameter not only demonstrated a significant change from 
baseline as early as 1 week post-treatment initiation but was capable of predicting clinical 
outcome in all of the studied patients. In contrast, conventional mono-exponential ADC 
(comparable to ADC120–1200 in this study) was only capable of predicting response in about half 
of their patient population. It is not clear whether R, as presented by Mardor et al., is driven by 
D1 or V2, or if D1 or V2 alone would provide ample sensitivity to predict tumor response to 
treatment as this analysis was not provided in their study. We further evaluated the approach 
proposed by Mardor et al. [6] (D1/V2) using our data. The percentage change in D1/V2 from 
baseline was ~42% in the treated group at day 6 post-treatment, which was significantly different 
from controls [2% (P = 0.002)]. Although, D1/V2 demonstrated a percentage change 1.6x 
greater than that generated by D1, this increase was not statistically different (P = 0.15). The 
probable cause for the lack of significance was the additional scatter in the data as a result of the 
nonlinear fit. Unlike DWI at moderate b-values, acquisition of diffusion-sensitized signal at b-
values of >2000 sec/mm
2
 is not trivial. This is attributed to the exponential loss of signal due to 
increased attenuation at high b-values. As signal approaches the noise floor, artificial 
nonmonoexponential trends in the signal profile are observed, adversely affecting the slow 
diffusion measurements. To accommodate these losses, images must be acquired with sufficient 
SNR resulting in longer scan times, which may not result in patient compliance. Additional 
computational time is also required when fitting the biexponential formalism to the DWI data. In 
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this study, ~30 min per dataset was required for the voxel-wise nonlinear fit. The stretched-
exponential formalism does not suffer from this deficiency because it can be linearized and 
solved using an algebraic solution of the linear least squares. Numerically fitting two parameters 
for the stretched exponential model can also be more stable relative to fitting three parameters 
required by the biexponential model. 
There are several limitations to our experimental approach that must be discussed. Scan 
time was limited to no more than 2 h. This in turn limited the signal averaging, i.e., SNR, and 
range and number of b-values used per scanning session. As discussed, large slice thicknesses 
and small matrix sizes were used to maintain our self-imposed constraint of SNR > 6. This likely 
resulted in unavoidable partial volume averaging in the tumor, which would be less with thinner 
slices. Another area of concern was the lack of sufficiently high b-values, which are most 
sensitive to “slow diffusion” rates. This could have possibly led to an overestimation of the D2 in 
the biexponential fit. Using the mean D1 and D2 determined at day 6 post-treatment initiation, we 








/sec), less than 4% 
(exp(2000*0.0017) ~3.3%) of the fast diffusion signal was still present at a b-value of 2000 
sec/mm
2
, whereas 29.9% of the slow diffusion component signal was still available. Finally, the 
biexponential diffusion coefficients, D1 and D2, acquired here for healthy striatum varied by only 
a factor of 2, contrary to the factor of 5–10 typically observed in the literature. Based on the 
observations of biexponential diffusion in rodent models, D1 as measured in this study is in 




/sec in the 
literature), whereas D2 appears to be overestimated by a factor of 2 (0.43 here, compared to 0.17 




/sec in the literature) [28, 41]. The discrepancy in D2 is most probably due to 
the lack of sufficiently high b-values used in this study. Finally, the filtering of low SNR voxels 
from our whole-tumor analysis may have inadvertently removed necrotic regions in the tumor. 
Signal intensity within regions of high diffusivity or short T2 due to blood products is prone to 
have low signal at high b-value. As discussed earlier, the contribution of noise in our data was 
reduced by filtering voxels whose SNR < 6 on the highest weighted DWI (4000 sec/mm
2
). This 
maintained voxels having high SNR at high b-values but removed regions of high diffusivity or 
low SNR (i.e., necrosis, cystic, and blood products) from the whole-tumor analysis. To avoid 
excessive loss of tumor volume while maintaining SNR  6, image matrix size and slice 
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thickness were set to maintain adequate SNR at a cost of resolution. The volume fraction of 
tumor analyzed at days 6 and 9 post-treatment initiation in treated animals was 93.5% ± 11.3% 
and 94.5% ± 9.9% (means 6 SD), respectively. Based on these values, filtering tumor regions 
that contribute to low SNR in DWI at high b-value did not result in excessive loss of tumor 
volume for our analysis in this study. 
We have demonstrated the sensitivity of various nonmonoexponential diffusion 
formalisms for monitoring early response to chemotherapeutic treatment for brain tumors in an 
animal model. The extent of the response varied, with the fast diffusion component of the 
biexponential formalism exhibiting the largest percent change from baseline than other diffusion 
coefficient; slightly more than was observed in the conventional monoexponential ADC and 
DDC measurements. However, for this 9L glioma model treated with a single dose of BCNU, the 
more complicated formalisms provided no additional sensitivity to treatment response over what 
was observed using conventional mono-exponential ADC measured over the standard modest b-
value range. 
1.2: Diffusion Model Sensitivity Analysis 
1.2.1: Introduction 
As was discussed in the previous section, true water diffusion in living tissues is very 
complex, relying on various structural and chemical properties intrinsic to the tissue. In finding 
useful quantitative readouts from the limited information obtained from diffusion-weighted 
imaging, it is necessary to distill the assumed phenomenon down to a simpler, more manageable 
model. In measuring tissue response, the model readouts must be related to real physical 
properties in order to derive meaning from the data. 
Due to the unavoidable noise associated with quantitative image values, it is important to 
characterize the error associated with parameter readouts when fitting the model to data. In 
performing a sensitivity analysis of the model, we can determine which model parameters most 
affect the output as well as which will show the greatest sensitivity to a small change in the 
acquired data. A greater magnitude change in the sensitivity coefficient is indicative of a greater 
ability of the model to detect a change in the image data curve, which would be a useful property 
for an imaging biomarker. Also, by assessing the sensitivity of the fit parameters to noise we 
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may determine the expected accuracy of a measurement based on the image noise associated 
with data acquisition. 
In this section I will perform two types of analyses to characterize model sensitivity and 
robustness: sensitivity analysis and noise analysis. Local sensitivity analysis is a tool that can be 
used to quantify the reaction of the model relative to a change in an individual input parameter, 
one parameter at a time. This local sensitivity coefficient will be evaluated near the input space 
of a known reference point as optimized from real data from the previous section. Parameters 
that show relatively low sensitivity may have higher error in their optimization readout due to the 
smaller effect they have on the model. It is also important to determine the sensitivity of 
optimized parameters to noise in the data. For this analysis multiple optimizations were 
performed, each time fitting the model to simulated noisy data. It is expected that greater noise in 
the data will produce greater error in the modeled parameters. By comparing the parameter and 
noise sensitivities between models, a measure of model robustness and stability may be 
determined. Both methods were used on the previously-mentioned diffusion models and results 
are presented below. 
 
Table 1.2: Baseline diffusion model parameters for sensitivity analysis. 
 
1.2.2: Methods 
For each model (mono-exponential, bi-exponential, and stretched exponential), an initial 
fit was performed on a representative data set to obtain a set of model parameters to base 
sensitivity metrics upon. The fit was obtained using a manually-delineated volume-averaged 
signal intensity encompassing an untreated intra-cranial 9L tumor in a rat brain, approximating 




Model Sensitivity to Parameter Changes 
 A parameter local normalized model sensitivity coefficient, SC, was quantified as the 
partial derivative of the signal intensity model,  (        ), with respect to the parameter of 
interest, xi, at the reference parameter point, [            ], both normalized by their reference 
values [43] (Appendix A):  
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The values of SC were evaluated over the study’s range of b-values. 
Model Fitting Sensitivity to Noise 
Noise, in the case of MRI magnitude images used in this experiment, was modeled as a 
Rician distribution [44], which for high SNR can be approximated as Gaussian: 
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where A is the true image intensity,  is the standard deviation of the Gaussian noise, and I0 is 
the modified zero
th
-order Bessel function of the first kind. This noise model can be combined 
with the assumed noise-less image intensity curve using the following equation: 
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, [1.2.3] 
where the subscript i represents the i
th
 b-value, Si’ is the noisy signal, S is the noise-less signal, 
Ni() is a random number from the Normal distribution with standard deviation . Noise was 
tested at values of  set from 1 to 20% of the baseline voxel intensity values for each b-value. 
Since acquisitions using the diffusion sequence in the previous section were optimized for each 
diffusion-weighting separately, SNR was modeled as being equal for each b-value in the model. 
Noise simulation and subsequent fits were performed 500 times for each noise level. Curve-
fitting was performed in Matlab (The MathWorks, Inc., Natick, MA), using an un-weighted non-
linear least-squares algorithm and an initial guess based on findings in the previous section. 
Mean parameter error was determined by the following equation: 
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where p0 is the true parameter value and pi is the fitted parameter value from the i
th
 fit with noise 






Figure 1.2.1: Plots of parameter sensitivity analysis for each diffusion model, sensitivity 
coefficient vs. b-value, for: (A) mono-exponential, (B) stretched-exponential, and (C) bi-
exponential. Each plot shows three curves using varying reference values for the parameter of 
interest (blue = low, green = middle, and red = high). 
Model Sensitivity to Parameters 
Plots of the sensitivity coefficients over the range of b-values used in the previous section 
are shown in Figure 1.2.1A-C, with the zero-sensitivity threshold plotted as a gray horizontal 
line. Each plot shows the model sensitivity to the indicated parameter at three different levels of 
that value. All input parameters for all models have minimal sensitivity at low b-values, with 
general increases in sensitivity with b-value, and lower sensitivity over the range of b-values for 
lower values of the parameter. The mono-exponential ADC sensitivity coefficient (Figure 
1.2.1A) decreases linearly with b-value, resulting in high negative sensitivity at higher b-values. 
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This indicates that a small increase in ADC will have a drastic effect on high b-value diffusion 
image signal intensity. Sensitivity plots of ADC and DDC (Figure 1.2.1B) look very similar, but 
when SCDDC is analyzed at lower values of 0 (higher diffusion coefficient heterogeneity) the 
shape shifts from negative linear to exponential with diminishing slope magnitude at higher b-
values (not shown). The stretched-exponential parameter, , also has very low sensitivity and 
actually has zero sensitivity around b = 1000 s/mm
2
 in this case. Looking back at the model, this 
occurs where         and   ( )    (Appendix A). In the case of the bi-exponential model 
(Figure 1.2.1C), however, Df reaches a maximum sensitivity at high values of Df,0 and starts to 





/s) within the selected range of b-values. The diminishing magnitude of 
sensitivity to Df is balanced by the increasing sensitivity magnitude of Ds and fs. In general for 
these models, the sensitivity coefficient also has a trend of decreasing the individual parameter 
sensitivity with an increasing number of input parameters to the model.  
Model Fitting Sensitivity to Noise 
Plots in Figure 1.2.2 show results from model fits to simulated noisy data, presented as 
the mean absolute parameter measurement error plotted against the signal-to-noise ratio (SNR) 
and separated by model. As would be expected, lower SNR resulted in exponentially greater 
error in parameter estimation. The mono-exponential model (Figure 1.2.2A) showed the least 
sensitivity to noise, with ~6% measurement error at an SNR of 10. The bi-exponential model 
(Figure 1.2.2B) on the other hand had the greatest sensitivity to noise overall, with average errors 
at SNR=10 of 57%, 104%, and 392% in Df, Ds, and fs, respectively. At SNR=100 errors in ADC, 
DDC, and  were less than 2%, but bi-exponential parameter errors were still fairly significant 
with means of 7%, 41%, and 79% for Df, Ds, and fs, respectively. Figure 1.2.2d shows an 
increasing trend of diffusion coefficient optimization error with the number of model inputs, with 






Figure 1.2.2: Plots of noise analysis results, with (A-C) mean absolute percent change 
plotted against baseline SNR and (D) comparison between diffusion coefficients of the three 
models at SNR=100. Errors are shown as ± SEM (too small to see on the mono-exponential 
plot). 
1.2.4: Discussion 
Diffusion MRI has been shown to be useful in detecting tumor response to therapy using 
various pre-clinical tumor models as well as clinical studies. Recent findings of non-mono-
exponential diffusion behavior in living tissue spurred increased interest in determining a more 
suitable diffusion model for quantification of these images [21]. For the purpose of this 
manuscript, two established models (stretched-exponential [29] and bi-exponential [21]) were 
evaluated against the traditional mono-exponential formalism in order to determine their stability 
and sensitivity in detecting changes in tumors due to therapy. 
Noise in magnitude MRI has been well-characterized [44], and its effect is critical to 
diffusion MRI in which signal is expected to significantly drop at high b-values. In order to 
maintain high SNR in high b-value images, multiple averages are often used on an image-by-
image basis, allowing SNR not to vary over the course of diffusion weighting. However, this 
limits the practical range of b-values by time limitations of image acquisition. Deviation from 
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mono-exponential diffusion behavior has been shown to occur only at high b-values (> 2000 
mm
2
/s), which can be seen in the sensitivity plots as an increasing SC with b-value when 
evaluating  in the stretched-exponential model and Ds and fs in the bi-exponential model 
(Figure 1.2.2). Due to the limited range of diffusion weighting, the high end of the diffusion 
curve is often under-sampled, as seen in the higher overall sensitivity of ADC, DDC, and Df 
compared to other parameters in this range, and leading to elevated measurement error in those 
model parameters. This can be seen in Figure 1.2.2 with very high error in fs and Ds compared to 
the stability of ADC, which even at SNR of 10 provides measurements with only 6% error. In 
fact, the bi-exponential model was found to be highly un-stable, with varying results depending 
on the initial parameter guess in the fitting algorithm. Introduction of a weighting factor based on 
SNR or higher b-values may help to stabilize bi-exponential results, but was not performed in 
this study. It is also generally found that an increase in the number of input parameters to a 
model increases the likelihood of non-negligible interactions among the parameters [43], which 
can be seen by the increasing measurement error of the “fast” diffusion coefficient with 
increasing number of input parameters at SNR of 100 (Figure 1.2.2D). 
In conclusion, more complex models of the underlying diffusion mechanism may provide 
useful insight into the biological response to treatment. However, increasing model complexity 
may also be expected to result in an increase in the uncertainty of the optimization which 
introduces greater error into the measured parameters. For the purpose of detecting diffusion 
changes in living tissue, the traditional mono-exponential model appears to be the most stable 
while still providing the necessary sensitivity to detect small changes. Within this range of b-
values, the bi-exponential model has insufficient data to be able to accurately measure the slow 
diffusion coefficient, and consequently has trouble separating Ds from Df, resulting in very high 
error in fs. Therefore, within the currently feasible range of diffusion weighting (i.e. b-values), 
the standard mono-exponential model provides the most robust readout as an imaging biomarker 
for therapeutic response assessment in tumors. 
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 Permeability (DCE)-MRI Chapter 2:
2.1: Permeability-MRI Treatment Response to VEGF Blockade 
Included with permission from John Wiley and Sons: 
Hoff BA, Bhojani MS, Rudge J, Chenevert TL, Meyer CR, Galbán S, Johnson TD, Leopold JS, Rehemtulla 
A, Ross BD, Galbán CJ. DCE and DW-MRI monitoring of vascular disruption following VEGF-Trap 
treatment of a rat glioma model. NMR Biomed. 2012 Jul;25(7):935-42. 
2.1.1: Introduction 
In Phase III clinical testing, Stupp and colleagues demonstrated the efficacy of concurrent 
temozolomide and radiation for treating newly diagnosed glioblastoma [1]. With an 
improvement of median survival from 12 months to 14 months, this treatment regimen has 
become the standard of care. Although radiotherapy plus concomitant temozolomide provides a 
clinically meaningful and significant survival benefit, the prognosis remains poor for most 
patients with malignant gliomas. A number of molecularly targeted therapies are being 
investigated for their potential to significantly improve the outcome for these patients [2, 3].  
Anti-angiogenic and antivascular therapies are at the forefront of development as viable 
treatment options for solid tumors [4, 5]. Recent clinical trials have shown that such agents, e.g. 
Bevacizumab, provide improved efficacy for the treatment of recurrent brain tumors [6]. The 
requirement of malignant gliomas for a continual supply of nutrients and oxygen provided by a 
vast network of newly forming intratumoral vessels provides a sound scientific rationale for 
targeting tumor angiogenesis. Vascular Endothelial Growth Factor (VEGF) is one of the 
principal driving forces for tumors to maintain their highly proliferative potential. Elevated 
stimulation of angiogenesis through the production of VEGF occurs predominantly in high-grade 
tumors [7]. Recent studies have also shown a significant reduction in both vascular permeability 
and neovascular formation in tumors treated with VEGF inhibitors [8-14] and have shown tumor 
regression in some cases [15]. VEGF-Trap (Regeneron Pharmaceuticals, Inc., Tarrytown, NY), 
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currently in clinical trials, is a decoy receptor protein effective in inhibiting VEGF signaling by 
binding with a high affinity to all isoforms of VEGF-A and placental growth factor [9-11, 15-
20]. Preclinical studies have shown that this agent, when combined with standard treatments 
encompassing chemotherapy as well as radiotherapy, results in improved efficacy [21-23]. 
Ultimately, these treatments are aimed at indirectly inhibiting tumor growth and possibly 
inducing cell death by limiting the availability of vital nutrients, which may improve the 
effectiveness of conventional therapies [21, 22]. 
Efforts are being made to evaluate imaging modalities to provide biomarkers of 
therapeutic-induced alterations in the tumor vasculature. Monitoring of volumetric changes prior 
to and following treatment initiation is the current standard of practice for assessing treatment 
effects. Although effective in predicting clinical outcome to therapy, prognosis may take 2–3 
months following the start of treatment. Functional imaging complements traditional anatomical 
imaging for improved diagnosis and response assessment. Hemodynamic imaging techniques 
including dynamic contrast enhanced (DCE) and dynamic susceptibility contrast (DSC) MRI 
provide insights into tumor blood flow, blood volume and vessel permeability, which have 
shown promise as sensitive biomarkers of treatment-induced response [23]. Most notably, DCE-
MRI uses low contrast agent concentrations to produce signal enhancement, which can be 
tracked and fit to a pharmacokinetic model to extract such values as volume transfer constant 
(K
trans
), the flux rate constant between the extravascular extracellular space and plasma (kep), and 
blood plasma volume fraction (vp) [24-26]. DCE-MRI has been used successfully to show 
decreased K
trans
 in tumors very early after anti-VEGF treatments [8, 12, 13]. A decrease in K
trans
 
has been correlated with decreased growth rates and decreased levels of free VEGF, indicating 
effective drug targeting. The apparent diffusion coefficient (ADC), a quantitative measure of 
water mobility calculated from diffusion weighted (DW) MRI, has shown promise as a sensitive 
and reliable biomarker for cytotoxic therapies [27-30] that elicits a treatment-induced reduction 
in tumor cellularity [31]. Increased cell death has been correlated with an increase in ADC. In 
this study, DCE- and DW-MRI were used to evaluate cellular and hemodynamic response of 9L 






Animal tumor models 
9L glioma cells were obtained from the Brain Tumor Research Center at the University 
of California at San Francisco. The cells were grown as monolayers in 10 cm
2
 sterile plastic 
flasks in Dulbecco’s Modified Eagle Medium with 10% fetal bovine serum, 100 IU/mL 
penicillin and 100 mg/mL streptomycin, and 2 mM L-glutamine in a 37C incubator. Prior to 
implantation, cells were harvested by trypsinization, counted, and re-suspended in serum-free 
medium for injection. 
Tumor implantation was performed in 17 male Fischer-344 rats, 7 to 9 weeks old (Harlan 
Sprague–Dawley, Indianapolis, IN) weighing between 125 and 150 g. Briefly, animals were 
anesthetized with a ketamine/xylazine mixture (87/13 mg/kg) administered intraperitoneally. A 
small incision was made over the right hemisphere of the cranium. A 1-mm diameter burr hole 
was drilled through the skull using a high-speed surgical drill, and a 5-mL suspension containing 
2x10
5
 9L cells was slowly injected at a depth of 3 mm. The burr hole was filled with bone wax, 
and the surgical area was cleaned using 70% ethanol. Vetbond
®
 (3 M, St. Paul, MN) was used to 
close the incision until healed. 
Anti-angiogenic therapy 
Once tumor volumes reached 20–60 mm
3
 as determined using MRI, pre-treatment DCE 
and DW-MR images were acquired for all animals. Animals were then separated into two groups 
and were treated with either 25 mg/kg VEGF-Trap (n = 10) or 12.5 mg/kg human Fc (vehicle 
protein) (n = 7). Treatments were administered subcutaneously twice weekly for two weeks 
(Figure 2.1.1A). 
MRI scans 
MRI scans were performed on a 9.4 T, 16 cm horizontal bore Varian (Palo Alto, CA) 
DirectDrive system with a quadrature rat head coil (Doty Scientific, Inc., Columbia, SC). During 
all MRI procedures, animals were anesthetized with a 1–2% isofluorane/air mixture and body 
temperature was maintained using a heated air system (Air-Therm, World Precision Instruments, 
Sarasota, FL). MR images were acquired 24 h prior to treatment initiation and 24 h after each 
treatment (Figure 2.1.1A). Each MR experiment consisted of a fast spin-echo-based T1-mapping 
37 
 
sequence and DCE- and DW-MRI sequences with a total overall acquisition time for each 
imaging session of approximately 45 min. 
 
 
Figure 2.1.1: Diagrammatic presentation of study time points (A). Treatments are 
highlighted in green, MRI (both DCE and DWI) are highlighted blue, MRI and blood serum 
collection were performed on Day 11 (red), and histological samples were taken at 
approximately Day 12 (yellow). Plot showing relative change in tumor volume in control 
(diamond, solid line) and treated (square, dotted line) groups over the study time period (B). 
Treated animals generally showed a significant slowing of tumor growth compared to controls. 
Doubling times in the control and treated groups were 3.76 (± 0.325) and 5.32 (± 0.319) days, 
respectively (p = 0.004). Significance in relative change in volume between groups occurred at 
days 8 and 11 post-therapy. Data are presented as means ± SEM. Significance was assessed at 




DW-MRI was performed using a spin-echo sequence with a navigator echo for motion 
correction and gradient waveforms sensitive to isotropic diffusion [32]. Images were acquired 
using the following parameters: repetition time/echo time (TR/TE) = 4000/47 ms, field of view 
(FOV) = 30 mm, matrix size = 128 x 64, slice thickness = 1 mm, slice number = 13, and b-values 
(diffusion weighting) of 120 and 1200 s/mm
2
. 
DCE-MRI was performed using a T1-weighted gradient-echo sequence with the 
following parameters: TR/TE = 85/3.2 ms, flip angle = 20, FOV = 30 mm, matrix size = 128 x 
64, slice thickness = 1 mm, slice number = 13 and averages = 2. Image datasets were acquired 
over a 15-min period with a time resolution of 10.9 s. Following 1 min of scanning (~6 images), 
a bolus dose of gadolinium-DTPA (Magnevist, Bayer Healthcare Pharmaceuticals; 0.15 
mmol/kg, diluted 1:8.3 from 0.5 mmol/mL in 0.9% saline solution to 0.06 mmol/ml) was 
administered via tail-vein catheter at a rate of 4 mL/min. 
Image reconstruction and analysis 
Tumors were manually contoured on the low-b images from the DW-MRI sequence (b = 
120 s/mm
2
). These volumes of interest (VOI) were used to determine tumor volume and whole-
tumor mean values generated from quantification of DW-MRI and DCE-MRI data. Tumor 
doubling times were calculated for each animal from exponential fits in Excel (Microsoft, 
Redmond, WA) to each individual growth time course [33].  
Apparent diffusion coefficients were calculated from the two diffusion weightings (b-
values) using the following equation: 





(     )
⁄ , [2.1.1] 
where S1 and S2 are the signal intensities at b-values b1 = 120 s/mm
2
 and b2 = 1200 s/mm
2
, 
respectively, and ADC1-2 is the apparent diffusion coefficient obtained using b1 and b2. 
Tumor kinetic parameters were determined by a voxel-wise three-parameter fit on the 
acquired time-resolved T1-weighted images using a tri-exponential arterial input function (AIF) 
for blood plasma concentration (Cp) (12): 
   ( )     
(    )     
(    )     
(    ), [2.1.2] 
with A1 = 0.8259, A2 = 0.2230, A3 = 0.1565 mM, 1 = 1.220, 2 = 0.156, and 3 = 0.017 min
-1
. 
In this study, we followed the referenced contrast injection procedure used for this AIF and 
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assumed negligible differences in AIF over time as well as between animals. This AIF was 
incorporated into a generalized kinetic model, equivalent to the efflux-corrected Patlak model 
[34, 35]: 
   ( )   
     
∫   ( ) 






 is the volume transfer constant, kep is the flux rate constant between extravascular 
extracellular space (EES) and plasma, and vp is the blood plasma volume fraction. Fits were 
performed using an un-weighted non-linear least-squares algorithm with an initial parameter 
guess based on literature values, and goodness-of-fit (GoF) was monitored to confirm reliable 
results; GoF was defined as the normalized root mean square error. Baseline signal intensity was 
calculated as a mean from the first ~6 images before contrast injection excluding the first image 
due to non-steady-state signal. Tissue concentrations of contrast agent were determined using the 
following equation: 1/T1 = R*[Gd-DTPA]+ 1/T10. The relaxivity (R) was determined to be 5.5 
ml/(mmols) by acquiring T1 maps of 1 cm
3
 syringes filled with saline (0.5 M) and 13 Gd-DTPA 
concentrations ranging from 0 to 10 mM. The relaxation constant was assumed constant between 
animals and time points. T10 is the T1 of the tumor tissue prior to injection of contrast agent. T10 
was set to 2.5 s which was the average of T1 measurements obtained in each animal pre-therapy 
using a fast spin-echo sequence with the following parameters: five TR values of 5, 1.5, 1, 0.8 
and 0.6 s, with 1, 1, 1, 2, and 4 averages, respectively; effective echo time (TE)= 39.68 ms, echo 
train length (ETL) = 4, 2 dummy scans, matrix size= 128 x 256, FOV = 3 cm, slice thickness = 
1mm. Parameter maps of K
trans
, kep, vp, and GoF were saved for the tumor VOI. Non-enhancing 
tumor tissue within the VOI was excluded from the analysis due to the model’s inability to 
accurately describe the tissue’s kinetic properties. Therefore, voxels with lower than 0.35 GoF or 
0.002 vp were excluded in mean tumor measurements. All reconstruction and analyses were 
performed using in-house programs written in MATLAB (The Mathworks, Natick, MA, USA). 
Parameter maps shown in Figure 2.1.2 were interpolated to 256 x 256 matrix size for display 
only. 
Histology 
Three representative animals were randomly selected from each group for tumor 
histology at approximately 12 days post-treatment initiation (Figure 2.1.1A). 9L tumors from 
control and treated animals were placed in buffered formalin overnight, dehydrated in 70% 
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ethanol, and subsequently embedded in paraffin. Tissue sections were prepared for histological 
processing by routine techniques. Briefly, paraffin sections (5 mm thick) were cut on a 
microtome and heated for 20 min at 65C. Slides were de-paraffinized in xylene with three 
changes for 5min each, then rehydrated through an alcohol gradient for 2min each (100%alcohol, 
95%alcohol, 70% alcohol). Some sections were first stained using a Gill’s 2X hematoxylin 
solution followed by eosin, while others were stained using the rabbit polyclonal antibody to 
Von Willebrand Factor III (vWf) to highlight tissue vasculature, and counterstained for the 
nuclei. For counting tumor vasculature, representative fields were obtained from the vWf-stained 
slides at random on each of three controls and three treated tumor slices. Brown-stained areas 
greater than about 10 mm in diameter were considered positive stains for the purpose of 
counting. Positive stains were counted using ImageJ software (NIH) and used to quantify the 
difference between groups. On additional sections, ApopTag or Ki-67 stains were performed 
using standard techniques to highlight apoptotic or proliferating cells in the tumor, respectively. 
Assessment of free and bound VEGF 
Blood serum samples were collected through a tail-vein catheter 24 h after the final dose 
of VEGF-Trap (n = 7) or vehicle (n = 3) (Figure 2.1.1A). Samples were stored short-term in a 
3C refrigerator until being shipped on ice to Regeneron Pharmaceuticals for analysis.  
Free VEGF trap was measured using a sandwich ELISA method in which hVEGF165 
(Regeneron Pharmaceuticals, Inc.) diluted in 0.05 M carbonate-bicarbonate buffer was used as 
the capture protein at a concentration of 2 g/mL. The antigen was VEGF-Trap (Regeneron 
Pharmaceuticals, Inc.) prepared in 1% BSA (KP Labs). Samples and standard were incubated for 
2 h at room temperature and the excess was removed in subsequent washes. The bound material 
was then reported with a mouse monoclonal antibody (P10 G1F6, Regeneron Pharmaceuticals, 
Inc.) then a secondary antibody was used. Anti-mouse HRP (Jackson Laboratories) TMB 
substrate (Sigma, T8665) was used in the color development, the plates were read at 450–570 nm 
and results analyzed using the SoftMax Pro 5.3 (Molecular Devices). 
Bound endogenous rat VEGF was determined by an ELISA developed using the antibody 
to Rat VEGF164 affinity purified polyclonal antibody (R&D Systems, Cat#AF564) as the 
capture antibody. The antigen was prepared fresh with rVEGF bound to two molar quantities of 
the VEGF-Trap and allowed to incubate at room temperature for 1 h. This complex was used to 
41 
 
generate a standard curve. Samples were bound to the plate, and after washing away the unbound 
rVEGF the unknown and controls were reported with an anti-human Fc IgG (Sigma, A-0170). 
The captured protein used in this assay was recombinant rat VEGF at 2 mg/mL in 0.05 M 
carbonate-bicarbonate buffer. The antigen used was the mouse monoclonal antibody P10 
(Regeneron Pharmaceuticals, Inc.), which was reported using a goat anti-mouse antibody 
(Jackson Laboratories) and the samples were reported with an anti-rat antibody (Promega). The 
samples were diluted 1:1000 to dilute out the serum effects of this assay. 
Statistics 
A paired Student’s t-test was used to compare the percent change of parameter values 
between pre- and post-therapy time points for each animal. An unpaired Student’s t-test was used 
to perform group comparisons in percent change of parameter values at each time point and 
tumor doubling times. Results were declared statistically significant at the two-sided 5% 
comparison-wise significance level (p<0.05). Values are given as means ± SEM. 
2.1.3: Results 
Therapeutic intervention was initiated at tumor volumes of 35.8 ± 5.0 mm
3
 and 36.4 ± 8.6 
mm
3
 for VEGF-Trap therapy and vehicle-treated control animals, respectively. Based on ELISA 
analyses, VEGF-Trap proved effective at binding to virtually all endogenous VEGF with no 
detectable VEGF and excess VEGF-Trap within the blood samples tested (Table 2.1). Data for 
the control group were not presented due to the absence of VEGF-Trap and VEGF levels being 
below quantification. Low levels of endogenous VEGF in non-VEGF-Trap treated animals have 
been reported in previous studies [20, 36]. As shown in Figure 2.1.1B, inhibition of VEGF 
signaling within the tumor resulted in significantly larger percentage changes in control tumor 
volumes at 8 and 11 days post-treatment initiation than those observed for VEGF-Trap treated 
tumors (p<0.05). Tumor volume doubling times were also affected as evidenced by values of 




Table 2.1: ELISA analysis of endogenous VEGF. 
 
 
Figure 2.1.2: T2-weighted images with color overlays of parametric maps are shown for a 
representative animal in the control group (A–D) and the VEGF-Trap-treated group (E–H) prior-
to (Day -1, left image) and following (Day 1, right image) the initial treatment. The initial drop 
for the VEGF-Trap-treated group in K
trans
 (-27%), kep (-12%), and vp (-64%) can clearly be seen 
here (E–G). ADC shows a small, but significant drop (-7%) by the first day post-therapy (H). 
Tumor heterogeneity was observed at individual time points. Nevertheless response to VEGF-





Figure 2.1.3: Plots of relative change in kinetic and diffusion parameters for the treated 
group (diamond, dotted line) shown together with the control (square, solid line). A significant 
decrease in K
trans
 and vp occurred on the first day post-therapy and persisted throughout the 
study. Tumor ADC steadily decreased in VEGF-Trap treated tumors up to 15% from the initial 
value. In contrast, kep continued to decrease throughout the study. Data are presented as means ± 
SEM. Significance was assessed at p<0.05 and indicated by * under their respective p-values. 
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Representative vascular kinetic and diffusion parameter maps are shown as color 
overlays in Figure 2.1.2. Partial-volume effects are apparent in Figure 2.1.2, evidenced by 
reduced kinetic measurements on the periphery of the color overlays. In vehicle-treated animals, 
negligible changes in parameter values were observed one day post-treatment initiation 
compared to the pre-treatment baseline (Figure 2.1.2A–D). In striking contrast, a single treatment 
with VEGF-Trap resulted in a substantial decrease in all kinetic parameters (Figure 2.1.2E–H) 
consistent with successful drug targeting. In general, all kinetic parameters showed spatial 
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variability within the 9L tumors at any given time point. Nevertheless, a spatially uniform 
response to VEGF-Trap was observed throughout the tumor for all kinetic metrics. 
The two kinetic transfer constants, K
trans
 and kep, and blood volume fraction (vp) were 
found to be dependent on VEGF-Trap treatment, again consistent with strong effectiveness in 
target modulation by the drug (Figure 2.1.3). The reduction in K
trans
 was observed following the 
first day of treatment, with a significant difference in K
trans
 (27 ± 3.1%, p = 0.002) when 
compared to vehicle-treated animals. Similar trends were observed for vp with a change of 63 ± 
2.3% (p<0.001). Subsequent to the initial decrease, parameter values plateaued and remained 
stable throughout the rest of the treatment cycle. A gradual reduction in kep resulted in significant 
differences between the two treatment groups by Day 3 post-treatment initiation (Figure 2.1.3). 
The maximum change in kep (34.6 ± 5.8%, p = 0.007) was observed at Day 11. 
In line with the kinetic parameters, ADC values declined following VEGF-Trap treatment 
(Figure 2.1.3). Although not as pronounced as the changes in kinetic metrics, a significant 
reduction in the change in ADC values was observed in VEGF-Trap treated tumors when 
compared to controls for all time points after treatment. ADC values did not reach a minimum 
value until Day 8 with a percentage decrease of 17.8 ± 3.2% (p = 0.027). Although ADC values 
for VEGF-Trap animals increased slightly from Day 8 to 11, this change was not significant. 
Histological sections of representative animals from control (n = 3) and treated (n = 3) 
groups taken 24 hours after the last treatment (11 days post-initial-treatment) were subjected to 
H&E, Ki-67, Von Willebrand / Factor VIII (vWF) and ApopTag staining. As observed in Figure 
2.1.4, a 14% reduction in Ki-67 staining was observed for VEGF-Trap treated tumors. This 
difference, although consistent with reduced proliferative potential, was not significant (p = 
0.25). In contrast, vWF stained sections revealed that vessel numbers were significantly lower in 
VEGF-Trap-treated versus vehicle-treated animals (p = 0.011; Figure 2.1.5). Interestingly, 
ApopTag staining revealed that apoptosis appeared to be localized within the endothelial cells of 
the vasculature, as shown by heavily stained regions in Figure 2.1.6. In contrast, tumor tissue did 
not show significant staining, and was therefore not quantified and compared between groups. 
The results observed in Figure 2.1.6 are consistent with the loss in vessel number (Figure 2.1.5) 
as well the reduction in MRI-determined kinetic measures (Figure 2.1.3). However, loss of 
vasculature due to VEGF inhibition did not result in a reduction in tumor cellularity as depicted 
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by visual inspection of tumor nuclear staining as well as lack of significant ApopTag staining in 
the tumor (Figure 2.1.6). 
 
Figure 2.1.4: The proliferative potential of tumors following treatment with vehicle (A) 
or VEGF-Trap (B) was determined by Ki-67 staining of samples taken on Day 12. Positively 
identified nuclei were counted in randomly selected fields. Representative micrographs for each 
group are shown. The quantification of the nuclei for each treatment group in 3–6 randomly 
selected fields per subject (C). Insignificant differences in Ki-67 positive nuclei were observed 
between treatment groups (p = 0.25). Bar plots are presented as the mean number of nuclei and 




Figure 2.1.5: Tumor vasculature following treatment with vehicle (A) or VEGF-Trap (B) 
was determined by Von Willebrand factor staining of samples taken on Day 12. Positively 
stained vessels were counted in randomly selected fields. Representative micrographs for each 
group are shown. The quantification of the vessels for each treatment group in 2–3 randomly 
selected fields per subject (C). A significant decrease in the number of vessels occurred in 
VEGF-Trap treated animals (p = 0.011). Bar plots are presented as the mean number of nuclei 




Figure 2.1.6: Apoptosis and tumor cellularity following treatment with vehicle (A) or 
VEGF-Trap (B) was determined by ApopTag staining of samples taken on Day 12, 
superimposed on H&E. Extent of apoptosis and tumor cellularity were assessed by visual 
inspection. Representative micrographs for each group are shown. Treatment by VEGF-Trap 
resulted in massive apoptotic events in the tumor vasculature but negligible change in tumor 
cellularity when compared to vehicle-treated tumors. Healthy and apoptotic vessels are indicated 
by yellow and red arrows, respectively. A closer representative VEGF-Trap treated sample is 
shown in C, highlighting the border between tumor epithelial and vessel endothelial cells. 
Images were acquired at 20x (A&B) or 40x (C) magnification. 
 
2.1.4: Discussion 
The development of molecular targeted cancer therapies represents an area of intense 
investigation. Consequently, a number of clinical trials are underway encompassing a diverse 
array of targets and agents. However, the primary endpoint used for assessing therapeutic 
response continues to be gross tumor volumetric change. This endpoint may not be the best 
choice for measuring the effectiveness of those molecularly targeted agents that do not uniformly 
elicit a significant reduction in tumor volume [37-39]. Therefore, there is an impetus to explore 
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non-invasive quantitative imaging modalities, such as MRI and positron emission tomography 
(PET), for their potential to provide non-invasive biomarkers of treatment response. In fact, 
DCE-MRI and DW-MRI metrics have shown significant promise as biomarkers of early cancer 
therapeutic response [40, 41]. The goal of this study was to evaluate DCE-MRI and DW-MRI for 
their ability to detect and quantify the therapeutic response of glioma-bearing animals treated 
with VEGF-Trap. 
VEGF-Trap is extremely effective in binding VEGF and PGF [15, 18]. The extent of 
VEGF-Trap binding to endogenous VEGF was virtually complete following two weeks of 
treatment (Table 2.1). This strong binding affinity to endogenous VEGF was clearly evident 
early in our MRI measurements. Vascular kinetic rates and blood plasma volume fraction as 
measured by DCE-MRI were highly sensitive to VEGF-Trap treatment. Subsequent to the first 
treatment, both K
trans
 and vp diminished by approximately 30% and 60%, respectively, 
suggesting an extremely rapid response of tumor vasculature to VEGF-Trap. These vascular 
changes are reflected in our vWF and ApopTag histological stains (Figs 5 and 6), which show a 
lower number of vWF-positive-stained blood vessels and greater ApopTag staining of vessel 
endothelial cells in treated animals. These trends agree with those observed in both preclinical 
and clinical investigations of tumor response to anti-angiogenic and antivascular agents as 
measured by DCE-MRI [8, 41]. 
An increase in tumor water mobility as determined by ADC measurements has been 
associated with a reduction of tumor cellularity as a consequence of massive cell kill [27]. 
Treatment by VEGF-Trap elicited no such response in ADC values, suggesting no substantial 
decrease in tumor cellularity due to cell death. Staining by H&E and ApopTag corroborated what 
was observed by ADC. In fact, ADC values decreased significantly following VEGF-Trap 
treatment with a significant drop observed as early as one day post-treatment. Reiger and 
colleagues monitored changes in DSC-MRI and DW-MRI quantitative metrics during 
Bevacizumab treatment in glioma patients, observing a similar trend in ADC [41]. In their 
clinical study, a drop in tumor blood volume as well as water mobility within the tumor was 
reported by 8 weeks post-treatment initiation. The reduction of ADC was attributed to 
pathological changes in the tumor, which may result in a decrease in extracellular water content 
and narrowing of extracellular space due to treatment-induced hypoxia. This would result in an 
increase in tumor cellularity per unit volume, which is inversely related to ADC values.  
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Numerous models for assessing pharmacokinetic qualities in vivo with varying 
assumptions have been proposed. In this study we used an established model that assumes the 
fast exchange limit to analyze our DCE-MRI data. This technique has been well-documented but 
recent studies have provided more robust models including the shutter-speed approach developed 
by Yankeelov and colleagues in 2003 [35]. This model has shown greater accuracy in 
quantifying permeability kinetics but has only recently seen more extensive application. 
Although more accurate, the sensitivity of the newer models to therapeutic response have yet to 
be tested against established pharmacokinetic models. Such an analysis is beyond the scope of 
this study.  
The impairment of VEGF signaling activity in the 9L glioma model resulted in apoptosis 
of the vascular endothelial cell population, which likely contributed to the overall reduction in 
tumor vessel numbers. The observed decrease in tumor vessel density is also in agreement with 
previously reported results of the use of antivascular agents on gliomas [42-45]. However, in 
these previous studies, apoptosis of endothelial cells was not reported following VEGF-Trap 
treatment. Erber and colleagues showed that targeting VEGFR-2 and PDGFR-b signaling using 
the tyrosine kinase inhibitor SU6668 in a C6 rat tumor model resulted in endothelial cell 
apoptosis and reduced tumor growth rate [46]. This is in agreement with our results, which show 
a similar reduced growth rate as reflected in our volume measurements as well as Ki-67 staining 
(Figure 2.1.1B and Figure 2.1.4) that show a slightly diminished fraction of proliferating cells. 
In conclusion, this study supports the utility of DCE- and DW-MRI in monitoring the 
effectiveness of angiogenesis-targeted cancer therapy, in this case response to VEGF-Trap. The 
ability to track therapeutic effectiveness with non-invasive imaging biomarkers is especially 
important for gliomas because biopsies during the course of treatment are not an option (unlike 
most other histotypes that are amenable to pharmacodynamic biomarkers). The use of these MRI 
modalities is especially compelling as angiogenesis targets are prominently being tested in the 
glioma population. Besides Aflibercept (VEGF-Trap), there are a number of other targeted 
agents in current clinical trials for treating glioma patients, e.g. Zactima (vandetanib, 
ClinicalTrials. gov ID: NCT00272350), cediranib (AZD2171) [34], ramucirumab 
(ClinicalTrials.gov ID: NCT00895180), BIBF1120 (ClinicalTrials.gov ID: NCT01380782), as 
well as numerous bevacizumab (Avastin; ClinicalTrials.gov ID: NCT00782756) [47-49] 
combination trials. Studies are underway to extend this proof-of-principle to the study of the 
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broader angiogenesis portfolio to build a compelling case for clinical trial incorporation. Overall, 
MRI biomarkers have significant potential for not only monitoring treatment effects but also for 
optimization of drug dose and schedules. 
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2.2: Comparison of DCE-MRI Models 
2.2.1: Introduction 
Paramagnetic gadolinium chelates have been extensively used as contrast agents (CA) for 
both qualitative and quantitative MRI. Signal enhancement in contrast-enhanced MRI is due to 
an interaction between the injected paramagnetic contrast agent, usually Gd chelates, and the 
protons on water molecules commonly detected in MRI due to the high abundance of water and 
high gyromagnetic ratio of protons. These agents shorten the T1 relaxation time proportional to 
their concentrations, within a certain range, resulting in increased T1-weighted signal intensity. 
The injected CA, typically an intravascular agent, travels through the blood to a tissue of interest 
and in the case of aggressive tumors were vessels are compromised is able to leak into the 
extracellular extravascular space (EES).  
In order to quantify tissue vascular properties, the signal enhancement kinetics seen in the 
images resulting from a bolus injection of CA are fit to a pharmacokinetic model, most often a 
two compartment transfer model between blood and the EES [26]. Physical tissue properties 
such as a vessel permeability constant (K
Trans
) and the fractional volume of EES (ve) are typical 
model parameters that are quantified in DCE-MRI. Although these models work very well in 
fitting to dynamic data and produce reasonable measurements of the desired tissue properties, the 
physics of MRI signal enhancement are much less direct than these purely pharmacokinetic 
models would imply.  
A more recently developed model for use in DCE-MRI takes into account the mechanism 
of contrast enhancement in MRI as well as two-site water exchange between intra- and extra-
cellular water pools, named the shutter-speed model (SSM) [35]. Contrast agents are not able to 
enter the intra-cellular space, but water molecules are mostly found within the cell and are able 
to penetrate the cell membrane. Due to the non-instantaneous measurement of the water signal, 
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there will inevitably be some exchange of water between the intra- and extra-cellular spaces, 
resulting in a modulation in the detected signal intensity. This shutter-speed effect has been 
shown to result in significant underestimation of parameters values, as much as 50% [35]. The 
shutter-speed model takes this water exchange into account when determining the contrast 
enhancement, and provides an extra parametric readout of the mean intra-cellular water molecule 
lifetime. 
In the following, three popular DCE models are compared for the detection of parameter 
changes after VEGF blockade, using the same animal tumor model as was presented in the 
previous section. Similar parameters between the models are compared over the time course of 
anti-VEGF therapy and highlight differences in sensitivity for detecting tumor treatment 
response. 
2.2.2: Methods 
The data extracted from the animal experiments discussed in section 2.1 was used to 
explore several popular models of DCE-MRI signal enhancement due to contrast agent 
distribution in tissues [26, 35].  
Models: 
Tofts-Kermode (TK) 
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     ∫   ( ) 




This model considers tissue concentration change as the exchange of contrast agent (CA) 
between two compartments, blood plasma and extra-vascular extra-cellular space (EES). Here, 
Cp is the blood plasma concentration of CA, and the two optimized parameters are K
Trans
, the CA 
transfer rate constant between blood and EES, and ve, the tissue volume fraction of EES. 
Efflux-Corrected (Patlak) 
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This model is similar to the TK formalism, but takes into account a blood plasma tissue 





Shutter-Speed Method (SSM) 
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This model combines two-site-exchange processes (between intra- and extra-cellular 
water) with the pharmacokinetic model of CA dynamics, resulting in an additional time constant 
term, τi, which describes the mean intracellular lifetime of a water molecule in the voxel. In this 
formalism, the parameters L and p0 may be translated to K
Trans
 and ve (for comparison to the 
other two models) by the following relations, where fw is the tissue water volume fraction 
(assumed to be 0.8 [35]): 
          [2.2.5] 
                     [2.2.6] 
Area Under the Curve (AUC) 
The AUC was determined as the integral of the signal enhancement curve over the time 
course of the experiment. This measurement gives a general sense of the mean signal 
enhancement over the entire time course, with leakier tumors having higher values and normal 
tissue with low values. 
Statistics 
In fitting the model to data, a goodness of fit (GoF) was also calculated as the normalized 
root mean squared deviation (NRMSD, between model and data) on a voxel-wise basis and 
averaged over the tumor volume. All significant differences between like parameters were 
evaluated at individual time points using a Student’s two-tailed paired t-test and significance was 
assessed at values below p=0.05. Data in the plots are presented as the mean with error bars 
representing the standard error of the mean. 
2.2.3: Results 
For the purpose of model comparison, SSM model parameters, p0 and L, were converted 
to values of ve and K
Trans
 using the above equations 2.2.4-5, respectively. Figure 2.2.1 shows 
plots over the course of treatment of the percent change in average tumor (A-C) model 




goodness of fit to the DCE data. A significant decrease in K
Trans
 is present one day after 
treatment initiation, and was maintained throughout the study period, for all models. Significant 
differences were also seen at almost all time points and between all models, with the exception 
of day 4 post-treatment between the TK and SSM models (p=0.06). Values for ve only 
significantly changed from baseline levels on day 4 as determined by Patlak and SSM, but not 
TK. Also on day 4, the SSM model detected a significantly greater decrease in ve than the Patlak 
and TK models, and the percent change was also significantly lower than the TK model on day 
11. Both vp and τi, in the Patlak and SSM models, respectively, dropped significantly by day 1 
and remained low until the end of the study. AUC also dropped significantly after treatment, 
indicating an overall decrease in signal enhancement within the tumor. 
 
 
Figure 2.2.1: Plots over time show differences between models in comparable parameters 
means of (A) K
Trans
, (B) ve, and (C) tertiary parameters (τi from SSM and vp from the Patlak 
model). Plots over time of the (D) mean tumor area under the signal intensity curve (AUC) and 




As seen in Figure 2.2.1E, the Patlak model generally had the best fit to the data, but no 
significant difference in GoF was found between any of the models at any time point. For all 
models, the NRMSD increased after treatment and remained elevated throughout the study 
(significantly higher on days 1 and 4). 
2.2.4: Discussion 
VEGF, which is often over-expressed in cancer cell lines, is known to stimulate the 
formation of blood vessels critical for the continual growth of the lesion. Neovasculature has 
been shown to have more irregular spacing and results in greater leakiness than established 
vessels. From the perspective of DCE modeling, this results in a high transfer rate, K
Trans
, from 
the blood to the EES, as well as a high fractional blood volume in the tumor. VEGF inhibition 
would therefore be expected to decrease both K
Trans
 and vp, which was observed in this study.  
In searching for an imaging biomarker, the observed readout should be related to a 
specific physiological response as well as providing the greatest contrast between pre- and post-
therapy states. Overall, the SSM model parameters appear to be the most sensitive to anti-VEGF 
treatment, with substantial drops in both K
Trans
 (-57%) and τi (-35%) within one day of the first 
treatment, even though the model seemed to result in the poorest fit to the data. Values of K
Trans
 
determined by the TK (1.6 ± 0.1 [x10
-4
] /s) and Patlak (1.3 ± 0.1 [x10
-4
] /s) models on day -1 
were approximately 28% or 40% lower than those found using the SSM model (2.7 ± 0.5 [x10
-4
] 
/s), respectively, similar to findings reported by Yankeelov et al. [35]. This underestimation of 
K
Trans
, however, did not persist after treatment, which agrees with the significant drop in the 
SSM parameter, τi, and indicates a faster water exchange between intra- and extra-cellular water. 
The Patlak model’s vp parameter was also very sensitive, with a 60% drop within the first day, 
but it had the least sensitive K
Trans
 (-24%) readout compared to both other models. For all 
models, ve was found to be an insensitive biomarker for this type of therapy. The increase in 
NRMSD for all models after treatment corresponds well with the decrease in AUC, indicating an 
intuitively increased error due to lower signal. 
In conclusion, all models were sensitive to vascular changes induced by this VEGF 





, vp, and τi) were significantly more sensitive than the TK (K
Trans
), 
indicating that they would be better-suited as an imaging biomarker in this case. 
2.3: DCE Model Sensitivity Analysis 
2.3.1: Introduction 
As was previously mentioned (Section Diffusion Model Sensitivity Analysis), when 
determining a model’s usefulness in providing sensitive biomarkers for indication of treatment 
response it is important to understand the reliability of its readout.  
2.3.2: Methods 
Analytical methods of testing local parameter sensitivity and model sensitivity to noise 
are described previously (p. 25). The base model is in the form of either tissue gadolinium 
concentration, Ct (TK, Patlak), or R1 (SSM), which can be translated to signal-based models, and 
thus the sensitivity coefficient (SC), using the chain rule (Appendix A). Sensitivity coefficients 
were evaluated over the time course of the experiment. Baseline parameters for each model are 
shown in Table 2.2. 
 
Table 2.2: Baseline DCE model parameter values. 
 
2.3.3: Results 
Model Sensitivity to Parameter Changes 
Figure 2.3.1 shows plots over the imaging time course of SC for each model: (A) TK, (B) 
Patlak, and (C) SSM. For the SSM, sensitivity for the parameters L and p0 are shown, but their 
sensitivity coefficients are equal to those of their converted counterparts, K
Trans





Figure 2.3.1: Plots over the time course of DCE model sensitivity coefficient for (A) 
Tofts-Kermode, (B) efflux-corrected Patlak, and (C) shutter speed (SSM) models. For the 
purpose of comparison of SSM parameters to the others, SC(L) is equivalent to SC(K
Trans
) and 
SC(p0) is equivalent to SC(ve). Each plot shows dS/dpi, where pi is the parameter of interest, for 
three reference values of pi (blue = low, green = mid, and red = high). 
 
All parameters show zero sensitivity at the beginning due to the delay between the start 
of imaging and the arrival of the CA bolus to the tissue. K
Trans
 and ve sensitivities are almost 
identical between the TK and Patlak models, as the only difference between the two is the 
additive vp term in the Patlak model. All models’ K
Trans
 values show similar trends, with an early 
increase to peak, then fall past 0 to greater negative magnitudes toward the end. L, in the SSM 
model, however is about 1/10 the SC(K
Trans
) in the other two models and has a very sharp peak, 
coinciding with the bolus of CA and indicative that it is highly influenced by Cp. This is similar 
to vp sensitivity from the Patlak model, which is more directly affected by Cp, but vp has a high 
sensitivity compared to ve and K
Trans
. A greater difference in SC shape can be seen between the 
parameters ve and p0, where SC(p0) reaches a peak around 290 seconds while SC(ve) does not 
peak within the time of the experiment.  
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A general trend within almost all parameters is that higher reference parameter values 
result in higher overall sensitivity coefficients. The exception is τi, which has lower sensitivity 
with higher reference value. 
Model Fitting Sensitivity to Noise 
 
 
Figure 2.3.2: Resulting mean absolute error plotted against SNR for Tofts-Kermode 
(blue), Patlak (red), and Shutter-Speed (green) models. K
Trans
 and L parameter errors (A) are very 
similar between models, as are ve and p0 parameter errors (B), with ve from the Patlak model 
substantially lower than the other two above SNR=15. Additional DCE parameter errors, for vp 
(Patlak) and τi (SSM), are shown in (C). Parameter errors were also plotted against each other for 
a SNR of 25 (D), which is typical for DCE-MRI images. Error bars are standard error of the 
mean. 
 
Figure 2.3.2 shows plots of parameter errors over a range of SNR, from 10 to 100, for (A) 
K
Trans
 (and L), (B) ve (and p0), and (C) vp and τi. In all models, K
Trans
 (L for the SSM model, 
Figure 2.3.2A) has very similar sensitivity to noise, with slightly higher error in the SSM model. 
Measurement errors of ve (p0 for the SSM model, Figure 2.3.2B) were also very similar between 
models, with the Patlak model’s error lower than the other two. Tertiary parameter errors for the 
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Patlak and SSM models, vp and τi (Figure 2.3.2C), respectively, show a very low error in τi 
above SNR=15 and a very high error in vp under SNR=50. Figure 2.3.2D compares these 
parameters for SNR=25, which is typical for pre-clinical DCE-MRI acquisitions.  Of all models, 
the parameter with the highest sensitivity to noise was vp, with 40% error at SNR=20, and the 
lowest sensitivity to noise was τi, with 1% error at SNR=16.7. 
2.3.4: Discussion 
The sensitivity analysis presented here demonstrates how similar parameters from 
different models can have drastically varying behaviors. Although the TK and Patlak models 
behave very similarly due to the minimal difference between them, the SSM model exhibits less 
sensitivity to the transfer rate constant (L) than the other two (K
Trans
) by an order of magnitude. 
Despite this difference, K
Trans
 and ve parameters exhibit very similar noise error behavior. The 
Patlak model’s vp parameter had the highest SC overall, but was also very sensitive to noise, 
making it an unreliable readout at low SNR. On the other hand, the τi parameter in the SSM 
model also had high SC, but was the least sensitive to noise, making it a very good candidate for 
an imaging response biomarker. 
DCE-MRI images are acquired using a T1-weighted gradient echo sequence that typically 
has SNR on the order of 25, which, according to the above simulations, may result in possible 9-
12% errors in K
Trans
 or L readouts and 3-10% errors in ve or p0 readouts. Based on this sensitivity 
analysis, the SSM model appears to be the best choice for accurately detecting treatment 
response in this model as long as τi is expected to change. The high model sensitivity to τi and 
low sensitivity to noise coupled with the drop in both K
Trans
 and τi seen in section 2.2 make this 
model stand above the TK and Patlak models.   
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 Multimodality Imaging Chapter 3:
3.1: Multimodality Imaging of Bone Metastatic Cancer 
Included with permission from the editor of Translational Oncology: 
Hoff BA, Chughtai K, Jeon YH, Kozloff K, Galbán S, Rehemtulla A, Ross BD, Galbán CJ. Multimodality 
imaging of tumor and bone response in a mouse model of bony metastasis. Transl Oncol. 2012 
Dec;5(6):415-21. 
3.1.1: Introduction 
Bone metastases occur in more than 70% of advanced breast cancer patients with 
complications including bone fracture, pain, and spinal compression [1]. More than 250,000 
patient deaths worldwide result from breast cancer, mainly attributed to metastatic disease [1]. 
Current treatments include systemic cytotoxic drugs, as well as bisphosphonates used for 
inhibition of bone loss, and are limited in their efficacy for combating bony metastasis [2, 3]. 
Much recent research has been focused on targeted agents that disrupt specific closely involved 
signaling pathways in cancer. Effects of these treatments can be highly complex, which present 
challenges for the characterization of treatment response owing to the numerous mechanisms 
involved [4]. For example, recent studies in skeletal metastases have revealed important 
interactions between the tumor and its microenvironment [5-9]. It is well known that bone tissue 
harbors a latent pool of transforming growth factor–β (TGF-β) that when released by bone 
resorption propagates cancer growth in skeletal regions [2, 10-12]. The discovery of this 
interdependency has spurred development of new targeted drugs to inhibit this cycle, resulting in 
a spectrum of agents targeting various stages of the cycle including TGF-β receptors in cancer 
cells, RANK in osteoclast precursors, cathepsin-K, and bisphosphonates for inhibiting osteoclast 
activity [11]. Conventional anatomic imaging and histologic techniques for quantifying response 
to therapy are insufficient for capturing the time-dependent interactions and targeted mechanisms 
of this complex system. Conventional approaches to monitoring cancer response to therapy are 
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limited, with the most prevalent being changes in tumor volume followed by quantitative 
measurements of tissue perfusion and diffusion. Because of the unconventional action these 
agents have on metastatic breast cancer to the bone, a more comprehensive assessment of tumor 
biology and response to intervention would provide investigators developing new targeted agents 
with improved insights into the complicated interrelationships of the signaling pathways and 
their role in tumor growth and cell death. 
In this study, a multimodality approach to imaging treatment response was undertaken in 
an effort to more fully delineate the underlying biologic responses to bisphosphonate and taxane 
treatment using a mouse model of established breast cancer metastasis to the bone. Molecular 
resonance imaging (MRI) was used to monitor tumor soft tissue volumetric response and 
cellularity; micro-computed tomography (μCT) was used to monitor bone characteristics; 
bioluminescence imaging (BLI) was used to monitor apoptosis by measuring caspase-3–linked 
activation; and fluorescent probes targeting bone mineralization and cathepsin-K activity were 
used to provide information related to bone remodeling activity. Noninvasive imaging provided 
for longitudinal assessment of differential treatment effects on bone and tumor following 
administration with docetaxel and zoledronic acid (ZA). Imaging readouts were able to follow 
signatures unique to response of tumor and bone, revealing the capability of applying imaging 
modalities to “unmix” the complex biologic responses to individual therapies, thus providing 
opportunities for assessing more complex treatments targeting mixed osteoblastic and 
osteoclastic phenotypes. Overall, the application of multiple imaging approaches described 
herein provide a more comprehensive and robust process than any single-modality approach for 
new drug evaluation and efficacy screening through delineation of treatment effects on tumor 
and bone morphology as well as functional and signaling pathways. 
3.1.2: Materials 
Animal Tumor Model 
Female severe combined immunodeficiency mice were subject to intratibial implantation 
of MDA-MB-231 breast cancer sub-line 1833 cells transfected with a luciferase reporter on 
caspase-3 (Figure 3.1.1, PPOP [13], Promega Corporation, Madison, WI) in the right leg with 
10
5
 cells in 5μl of serum-free medium suspension. Briefly, mice were anesthetized with an 





 insulin syringe was used to bore a hole down into the tibial marrow space through the tibial 
plateau through which a Hamilton syringe was then used to insert the cell suspension. A sham 
injection of media alone was performed on the left leg as a surgical control.  
 
Figure 3.1.1: Diagram of the split luciferase construct used in this model. A split-
luciferase complex is expressed in the cells with a DEVD sequence between the N- and C-Luc 
domains, keeping the enzyme inactive through steric hindrance. When caspase-3 is expressed in 
the cell, signaling the cell to begin apoptotic events, active caspase-3 cleaves the DEVD 
sequence from the rest of the enzyme. Active luciferase then metabolizes luciferin substrate and 
emits light. 
Treatments 
Once tumor size reached a volume of 10 to 20 mm
3
 (as measured by MRI), mice were 
separated into treatment groups of ZA (n = 16), docetaxel (n = 7), or control (n = 17). ZA 
treatment was administered subcutaneously as 100μg in 100μl of phosphate-buffered saline 
(PBS, 5mg/kg) per mouse twice weekly for four treatments, docetaxel was administered 
intravenously at a dose of 20mg/kg weekly for three cycles, and control mice were administered 
PBS with the same schedule as ZA. Control animals treated with 10% ethanol were also 
considered but were found not to differ from PBS controls so are not shown. 
Imaging and Analysis 
Molecular Resonance Imaging 
MRI was performed using a 7-T, 16-cm horizontal bore DirectDrive System (Agilent 
Technologies, Palo Alto, CA) with a quadrature mouse head coil (m2m Imaging Corp, 
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Cleveland, OH). Images of the tumor-bearing leg were acquired twice weekly starting from the 
day before treatment initiation. Diffusion-weighted images were acquired using a spin-echo 
sequence with navigator echo motion correction and gradient waveforms sensitive to isotropic 
diffusion [14] using the following parameters: repetition time/echo time = 4000/37 ms, field of 
view = 20 × 20 mm, matrix size = 128 × 64, slice thickness = 0.5mm, slice number = 25, and b-
values (diffusion weighting) of 120 and 1200s/mm
2
. Following image acquisition, data that 
included manually drawing volumes of interest on the high diffusion-weighted image to compute 
tumor volumes and diffusion values were stored for analysis. Tumor volumes and apparent 
diffusion coefficient (ADC) values were quantified over time to monitor tumor burden and 
cellularity, respectively.  
Micro Computed Tomography 
μCT imaging was performed weekly starting from the day before treatment initiation 
using a Siemens Inveon System with the following parameters: 80kVp, 500μA, 300-ms 
exposure, 501 projections over 360 degrees, and 49.2-mm field of view (56-μm voxel size). 
Volumes of interest were drawn over the tibia from the tibia-fibula junction to the tibial plateau, 
measuring mean bone volume and mineral density throughout the study to monitor bone 
resorption. 
Bioluminescence Imaging 
For imaging of the PPOP-transfected cells, mice were injected with 200 mg/kg luciferin 
(Promega), and up to five mice were imaged in a single BLI scan, acquiring a series of images to 
find the total photon peak flux over a whole-leg region of interest (ROI) for each animal. Images 
were acquired on the day of treatment initiation and days 7, 10, 14, 21, and 28 afterward. BLI 
data were quantified as total photon peak flux normalized by tumor volume as measured by MRI. 
Fluorescence Imaging 
Fluorescence images were acquired on an IVIS Spectrum System (PerkinElmer, Inc, 
Walther, MA) every other week using the two probes: Osteosense 800 and CatK 680-FAST 
(PerkinElmer, Inc). Fluorescent probes were injected intravenously 24 hours before imaging, and 
hair was removed from the hind legs the same day using Nair lotion. The following optical filter 




Excitation (nm) Emission (nm) 
430 500 580 640 
675 720 740 760 
745 800 820 840 
After acquisition, images were spectrally unmixed using Living Image software (Caliper Life 
Sciences) to separate the two probe signals from each other and autofluorescence. ROIs with the 
same area were placed over both the left and right legs and signal was measured as the ratio 
(right/left) of mean radiant efficiency to account for variation in fluorophore injection, 
physiology, and possible accumulation of fluorescent agent because of the high frequency of 
imaging.  
Statistics 
A Student’s t test was used to compare means between groups at each time point. Results 
with P < 0.05 were considered statistically significant. All plots represent mean ± SEM. 
 
Figure 3.1.2: (A) Plots of percent change in tumor volume for each group show 
significant cell kill in the docetaxel group, but no significant effect in the ZA group. (B) Plots of 
percent change in tumor ADC show elevated values in the docetaxel group after day 6, but no 
significant change in the ZA group. (C) Representative ADC overlays show isolated areas of 
increased ADC in the docetaxel group (red) as well as a dramatic decrease in tumor volume seen 




MRI was performed to monitor tumor volume and water diffusivity (ADC) twice weekly 
throughout the study (Figure 3.1.2). This modality was able to detect a significant retardation of 
tumor growth (Figure 3.1.2A) in the docetaxel-treated group by day 6 compared to the control 
and ZA-treated groups, which was followed by tumor shrinkage with no recovery within the 
study time frame. In addition, ADC values of the docetaxel-treated group were found to 
significantly increase by day 6 (Figure 3.1.2B), indicating that significant tumor cell death in the 
docetaxel group had occurred following treatment initiation. The ZA group, however, showed no 
significant difference from control tumor ADC values over the duration of the study although 
both trended downward, indicating that increasing density or packing of tumor cells occurred 
during the multifold volumetric increase in tumor size. Representative ADC map overlays for 
each of the animal groups (Figure 3.1.2C) revealed consistently low ADC values in the control 
and ZA groups, whereas localized regions in the docetaxel-treated tumors became elevated 
before and during tumor shrinkage. 
 
Figure 3.1.3: (A) Plots of overall luminescence of the tumor-bearing leg over time. 
Values are shown as the percent change of total photon flux (over a fixed-area ROI) normalized 
by tumor volume (as measured by MRI). (B) Representative radiance overlays show increased 
caspase-3 activity in the docetaxel group and minimal change in the control and ZA groups. * 




BLI of the PPOP reporter (Figure 3.1.3) revealed an increase in caspase-3 activity in the 
docetaxel group within 1 week of treatment, which remained elevated until the end of the study. 
Control and ZA groups both remained at baseline levels throughout the study, indicating that no 
significant apoptotic activation occurred. Representative bioluminescence images for each of the 
three groups (Figure 3.1.3B) showed that a stable low level of photons were emitted from the 
tumor sites in the control and ZA groups over time, whereas an increase in photon counts in the 
docetaxel group occurred (Figure 3.1.3B).  
 
Figure 3.1.4: (A) Plots of tumor-bearing bone volume from CT. The control group 
remained stable over the first two weeks followed by a sharp decline beginning at week 3. An 
increase in the ZA group was seen by the first week and remained elevated, while a significant 
increase was not seen in the docetaxel group until week 3 and almost reached the ZA group by 
week 4. (B) Representative image isosurfaces in the three groups. Controls presented successive 
bone degradation throughout the study. ZA-treated animals showed minimal changes in bone 
structure, with only fracturing caused by tumor growth. Docetaxel-treated animals showed some 
initial degradation through week 2 followed by recovery seen by week 4. * indicates a significant 
difference from the control group (p<0.05). 
 
To monitor bone changes with therapy, μCT imaging was performed weekly and bone 
volume within the proximal tibia was quantified over the 4-week duration of the study (Figure 
3.1.4A). Within 1 week of treatment with ZA, a significant increase in bone volume was 
detected, which remained elevated throughout the study. The docetaxel group showed a delayed 
bone response, with a significant increase in bone volume observed at week 3. Control mice 
were found to have a stable total bone volume until week 3 followed by significant bone 
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degradation. Representative images (Figure 3.1.4B) show progressive bone degradation in the 
control group throughout the study, whereas the ZA mouse’s bone seemed to have stabilized 
even though growth of the soft tissue tumor appears to be fracturing the bone in certain 
weakened locations. Docetaxel-treated mice showed delayed bone response, with significant 
recovery by week 4. 
 
Figure 3.1.5: Bar plots of fluorescent signals in the tumor-bearing leg from (A) 
Osteosense
 
800 and (B) CatK
 
680-FAST are presented as values normalized by the non-tumor-
bearing leg. The ZA group showed no significant difference from controls with either fluorescent 
probe, but the docetaxel group showed significant increases in Osteosense
 
800 uptake (A, black 
bar) on weeks 2 and 4 and a significant drop in CatK
 
680-FAST signal (B, black bar) on week 4. 
* indicates a significant difference from the control group (p<0.05). 
 
Fluorescence imaging (FLI) was performed to obtain a more functional assessment of 
bone remodeling, with Osteosense 800 indicating the extent of bone reformation and activatable 
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CatK 680-FAST indicating the level of osteolytic activity. The plots in Figure 3.1.5 show that 
significant bone remodeling changes occurred at weeks 2 and 4 in the docetaxel-treated group, 
whereas there was no significant change detected in the ZA or control group. The progressive 
increase in relative Osteosense 800 signal for the docetaxel group indicated that there was a 
significant amount of bone reformation by week 2, earlier than the CT-evaluated bone response, 
which was maintained until the end of the study. CatK 680-FAST signal also showed a 
significant reduction compared to controls in the docetaxel group by week 4. The control group 
showed a progressive increase in CatK 680-FAST signal, indicating tumor growth and increased 
activation of osteoclasts. The ZA group did show attenuated CatK 680-FAST activation, which 
would be consistent with the reduction in bone loss seen by CT but was not found to be 
significant, compared to controls. 
3.1.4: Discussion 
The goal of this study was to investigate the use of multiple imaging biomarker readouts 
to interrogate interrelated biologic responses involved in the treatment of bony cancers in an 
effort to provide a more complete understanding of the overall biologic effects in vivo. Current 
preclinical studies rely heavily on histologic analysis, where a number of subjects must be 
sacrificed at each time point in the study to assess tissue responses. However, with the increasing 
variety of noninvasive imaging tools available, successful longitudinal studies may be 
strategically planned to reduce total subject numbers while maximizing the amount of 
information that can be extracted from each subject. This method will be increasingly useful for 
the evaluation of new therapies that may have multiple targets and require simultaneous 
monitoring of multiple processes. In the case of metastatic bone disease, assessments of 
treatments that affect both the soft tissue tumor and mineralized bone are important because of 
the known biologic interactions between the two as well as clinical implications in avoiding 
skeletal-related events, e.g., fracture. As newer treatments may not be directly involved in 
causing cell death or other conventionally quantifiable tissue responses, optical imaging 
techniques can be applied to assess treatment-related alterations in multiple cellular processes in 
vivo simultaneously and longitudinally over time. Optical readouts of treatment effects can be 
obtained from activatable and targeted FLI probes as well as genetically engineered tumor cells 
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whose molecular signaling events can be monitored noninvasively by BLI, which compliment 
more traditional imaging techniques such as MRI and CT. 
The use of MRI and CT for evaluation of soft tissues and bone, respectively, has long 
been established. Quantification of tissue response to therapy using these imaging modalities has 
classically been through morphologic changes such as tumor or bone volume, with the more 
recent development of functional imaging techniques such as diffusion MRI [14-19] and 
perfusion measurements acquired by MRI or CT [20-23]. The recent trend in therapeutic 
research, however, is toward modification of specific cellular signaling pathways using targeted 
agents that may not have such drastic morphologic effects. With these new agents, conventional 
imaging approaches may not have enough sensitivity or specificity to determine treatment effects 
in vivo. In this study, we have presented a multimodality approach to evaluate treatment response 
using readouts obtained through pathway-specific optical imaging techniques backed by 
conventional μCT and MRI, which are clinically relevant modalities that provide more general 
information on morphology and gross tissue characteristics. We evaluated two treatments 
representing the extremes of either tumor-specific or bone-specific therapies to more easily 
illustrate the separate effects of these agents on the complex tumor-stromal interaction. Tumor 
ADC response has been tested on a broad range of cases and shown to correlate with cell death 
and often preclude any detectable change in tumor volume [14-19], however, ADC alone cannot 
determine the mechanism of cell death. The inclusion of caspase-3–coupled bioluminescence in 
this case provides the link between treatment and the specific mechanism. The significant 
increase in normalized BLI signal in the docetaxel group over the controls indicates that, through 
caspase-3 signaling, cells are undergoing apoptotic cell death. Tumor ADC values did not show a 
significant difference between docetaxel and control groups before tumor volume. This is 
attributed to MDA-MB-231 cell lines aggressiveness and high sensitivity to docetaxel. 
FLI results using our two probes shed further light on the bone remodeling processes 
resulting from the tumor and treatments. Where μCT provides a high-resolution view of the 
current state of the bone, FLI is sensitive to the balance between processes of bone formation and 
erosion. The significant increase in the Osteosense 800 signal and dampening of the CatK 680-
FAST signal for the docetaxel group indicates that induction of tumor cell kill and subsequent 
reduction in tumor burden has inhibited the tumor-stromal interaction, i.e., “vicious cycle” [2], 
and shifted the balance of osteoblastic and osteolytic activities toward recovery. Tumor 
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apoptosis, following effective treatment by docetaxel, led to a reduction in osteoclast recruitment 
and subsequently fewer cathepsin-K–expressing cells in that region, where even MDA-MB-231 
cells have been shown to express cathepsin-K [24]. In addition, the disruption of the tumor-
stromal interaction allowed for an up-regulation of osteoblastic activity as evidenced by an 
increase in Osteosense 800 signaling. As expected, treatment with ZA had no effect on tumor 
burden, suggesting that tumor signaling to the stroma was undisrupted during treatment. In 
contrast to what we observed using docetaxel, ZA did not significantly affect the Osteosense 800 
signal ratio that would have been presumed based on the μCT results where an increase in bone 
volume was observed. Although not significant, the CatK 680-FAST signaling was slightly 
reduced in the ZA group when compared to controls. This may indicate that ZA protects the 
bone by reducing the extent of osteolytic activity, in essence shifting total bone turnover in the 
presence of a tumor from bone erosion to bone formation [14-23, 25-30]. 
When using a strategy for assessing the efficacy of a therapy using a multimodality 
imaging approach, it is important to take into account the limitations of the desired imaging 
modalities when planning a study. MRI and CT are both able to capture relatively high-
resolution images, providing easily quantified volume and ADC measurements, as well as being 
translated to the clinic. These two modalities, however, do not provide any information about the 
signals or mechanics of the biologic system. In contrast, the optical techniques described here 
provide detailed information on biologic processes and signaling but are confined to preclinical 
use. BLI and FLI are known to present challenging hurdles for in vivo quantification, such as 
assumptions of light attenuation and scattering through tissues, limited spatial resolution, and 
error in the injected probe/substrate. In the presented work, the fluorescent signal in the tumor-
bearing leg was normalized by the signal in the sham leg to account for variability of injection 
and heightened Osteosense 800 signal in the growth plates. The poor image resolution of FLI 
complicates matters further by having to contend with spillover signal from the growth plates. 
Nevertheless, with an established imaging protocol for acquiring data, care in image post-
processing, and an appropriate model, these limitations can be overcome to provide a full picture 
of the effects of a therapeutic agent on a tumor-stromal microenvironment. 
Overall, the experiments presented here demonstrate the use of multimodality imaging 
techniques for detection and quantification of multiple interrelated biologic processes affected by 
therapeutic intervention in a model of metastatic bone disease. Although the treatments were 
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selected on the basis of their current clinical relevance and their targeted effects on bone or 
tumor cells, this generalizable approach is anticipated to be useful in future studies identifying 
responses to experimental agents by obtaining a more complete understanding of the signaling 
pathways affected. These and other cancer cell lines have already been successfully engineered 
to express luciferase linked to cellular signals such as AKT, TGF-β, c-MET, epidermal growth 
factor receptor (EGFR), and others [25, 28, 30-32]. In addition, a wide variety of in vivo 
fluorescent agents (activatable and targeted) are already available, for imaging of many diseases. 
Selection of optical imaging agents, cell lines, and other imaging modalities, such as 
permeability MRI for measuring tumor vasculature, requires careful evaluation of which 
experimental readouts provide the most relevant information for assessing the efficacy of a novel 
agent as a single or combination therapy. 
In summary, experimental therapeutic agents have traditionally relied on anatomic and 
functional imaging readouts of treatment response. With the emergence of optical imaging 
approaches including reporter cell–based constructs and activatable and targeted exogenously 
administered probes, the interdependence of treatment responses due to complex tumor-host 
interactions can be more fully delineated. BLI and FLI in vivo methods may be tailored to most 
diseases and treatment interventions and are complementary to MRI and CT imaging readouts. 
The use of a multimodality imaging strategy is anticipated to provide the pharmaceutical 
industry with cost-effective and efficient options for furthering overall drug development 
strategies. 
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 Parametric Response Map of CT Bone Chapter 4:
4.1: Detection of Bone Loss in a Rodent Model of Osteoporosis 
Included with permission from Elsevier: 
Hoff BA, Kozloff KM, Boes JL, Brisset JC, Galbán S, Van Poznak CH, Jacobson JA, Johnson TD, Meyer 
CR, Rehemtulla A, Ross BD, Galbán CJ. Parametric response mapping of CT images provides early 
detection of local bone loss in a rat model of osteoporosis. Bone. 2012 Jul;51(1):78-84. 
4.1.1: Introduction 
Osseous bone is a dynamic system naturally altering its microenvironment through 
osteolytic and osteoblastic processes throughout an individual's life. Factors that include lifestyle 
changes, pregnancy, hormonal status, disease and age can alter the homeostasis of bone resulting 
in increasing bone loss. This will lead to bone weakening and possibly orthopedic complications, 
such as fractures, that will have a direct effect on a patient's quality of life. Approximately 50% 
of women and 25% of men over age 50 will have osteoporosis-related fractures in their 
remaining lifetime [1] with 71% of patients over 90 years old showing signs of osteoporosis [2]. 
Osteoporosis is both a clinical as well as a financial burden with costs from osteoporosis-related 
fractures projected to reach 25.3 billion by 2025 [3]. Current clinical management of these 
patients is to continually evaluate bone mineral content in an effort to identify weakened limbs 
and avoid skeletal-related events (SRE). 
Dual-energy X-ray absorptiometry (DXA), a planar imaging technique, is employed as a 
quantitative imaging tool for the diagnosis of bone mineral insufficiency [4-7]. This imaging 
method provides a highly accurate measure of bone mineral density with subjective spatial 
context. Quantitative measurements from DXA are typically obtained through summary statistics 
from a region of interest where inclusion of healthy bone with those showing weakening will 
attenuate the sensitivity at identifying early bone loss. Three-dimensional imaging techniques, 
such as computed tomography (CT), have led to the development of protocols to quantify local 
bone changes over time [8]. Although CT provides higher spatial detail over DXA, as of yet no 
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real clinical gains have been made as CT suffers from the same deficiencies when acquiring 
quantitative measurements of bone loss as DXA. With increasing therapeutic options for treating 
osteoporosis such as bisphosphonates and RANKL inhibitors, there is a clear unmet clinical need 
to identify early and locally weakened bones to circumvent the onset of SREs. With the correct 
tools, treatment decisions could be made quickly, based on imaging results, to individually 
optimize therapy and orthopedic correction surgeries. 
Since its introduction in 2005, the parametric response map (PRM) when applied to 
quantitative imaging has been shown to improve the sensitivity at identifying early treatment 
response in cancer patients and is predictive of overall survival over what can be achieved using 
summary-statistical methods [9-15]. In brief, the PRM method involves spatially aligning serial 
pre- and mid-therapy quantitative images then individually classifying voxels based on the extent 
of change in the quantitative metric within the voxel. As such, the quantitative value within a 
tumor voxel may increase, decrease, or remained unchanged following treatment. Relative 
volumes of the three classifications are determined and used as outcome measures of response. 
At present, PRM has been demonstrated on different MRI-based quantitative imaging 
approaches, such as diffusion and perfusion MRI (in the case of diffusion MRI, PRM was 
referred to as the functional diffusion map) [10-18], as well as a variety of tumor types and 
locations [9-15, 17]. 
Although PRM analysis has been used exclusively for assessing therapeutic response in 
cancer, this technique may also offer a sensitive measure of bone tissue changes in patients 
suffering from bone loss, such as osteoporosis. To test its efficacy at identifying local changes in 
bone density resulting from an intervention (e.g. disease or treatment), we applied the PRM 
method to serially acquired CT data from a well-established rat model of osteoporosis [19, 20]. 
Animals were subject to ovariectomy (OVX) procedures, or sham for control, and legs were 
monitored weekly using CT imaging for four weeks following surgery. In the OVX model, it has 
been well documented that removal of the ovaries initiates bone degradation due to hormone 
deprivation that results in reproducible bone loss, characterized by site-dependent decreases in 
overall bone mass as well as diminished trabecular structure and cortical expansion [19, 20]. 
Volume fractions of increased Hounsfield unit (HU) value (PRMHU+) or decreased HU value 
(PRMHU−) as well as total bone volume (BV) and bone mineral density (BMD) were assessed 
temporally as clinically relevant measures of bone loss. After the fourth week of imaging, 
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animals were sacrificed and tibiae were harvested for μCT ex vivo imaging. We found that 
PRMHU− was able to detect bone mineral changes in the OVX model as early as two weeks post-
surgery while providing detailed spatial information on the extent and location of bone loss, 
while standard in vivo measurements of BMD changes based on statistical summary techniques 
were not detectable until 3 weeks post-surgery. Assessment of these clinically relevant measures 
of bone loss suggests that PRM may provide additional sensitivity as well as spatial information 
over standard approaches that can be used by clinicians for the early diagnosis of bone 
weakening and osteoporosis. 
4.1.2: Methods 
Animal model 
Twelve female Sprague Dawley rats, 16 weeks old, were obtained from Charles River 
Labs and housed randomly in cages (2 per cage) fed with standard rat chow and tap water. Rats 
were randomly divided into ovariectomized (OVX, n=8) and sham-operated control (n=4) 
groups. When the rats were 17 weeks old, bilateral ovariectomy operation from a dorsal 
approach was performed on the OVX group, while surgery with no ovary removal was 
performed on the Sham animals. Ovariectomy was performed using standard protocols [21]. 
Briefly, animals were given 0.3 mg/kg buprenorphine pre-operatively and anesthesia was 
achieved using 5% isofluorane in 1 l/min oxygen until unconscious. The eyes were lubricated 
and all animals received a bolus dose of 5 ml warmed Lactated Ringers subcutaneously. Rats 
were then maintained on a warming table during surgery. The site of incision as shaved and then 
prepped using warm chlorhexidine and saline. Skin incisions were made from the second to fifth 
lumbar vertebrae on each side, about 2 cm in length, using a scalpel blade. The retroperitoneal 
incisions were made ventral to the rector spinae muscles just caudal to the last rib. The ovaries 
were exteriorized by gentle retraction, and then a 5–0 Vicryl suture was placed around the cranial 
portion of the uterus and uterine vessels followed by removal of the ovary, oviduct and a small 
portion of the uterus. Skin and peritoneum incisions were closed with 5–0 Vicryl sutures, and 
then rats were recovered under heat lamp until ambulatory. A second dose of buprenorphine was 
administered 8 h post-surgery and incisions were observed daily until fully healed. The animal 




μ Computed tomography (μCT) 
In vivo imaging was performed on a Siemens Inveon system with the following 
acquisition parameters: 80 kVp, 500 μA, 300 ms exposure time, 501 projections over 360°, 49.2 
mm field of view (FOV, 96.1 μm isotropic voxel size). Imaging was performed one day prior to 
surgery and days 6, 13, 20, and 27 post-surgery, capturing both tibiae as well as the distal femora 
of each rat. Right tibiae and femora were excised on day 28 post-surgery and stored in PBS-
soaked gauze at −20 °C until ex vivo μCT imaging was performed.  
Ex vivo μCT imaging was performed on a General Electric eXplore Locus SP system 
with the following parameters: 80 kVp, 80μA, 1600 ms exposure time, 400 projections, 0.5° per 
projection, 4 frames averaged per projection, 18 μm isotropic voxel size. For imaging, the 
sample was submerged in water, and X-rays were pre-filtered using 0.02” aluminum. Each image 
captured the proximal tibia, from the tibial head to about 20 mm distally. 
In vivo image analysis 
PRM analysis was performed using Matlab (Natick, MA) algorithms developed in-house. 
In vivo CT images were converted to Hounsfield units using a 0 HU phantom on each time point. 
All post-OVX image time points were registered to baseline images using mutual information as 
an objective function and simplex as an optimizer [22]. Registration was automatic and assumed 
rigid-body geometry, meaning rotation and translation only. Bone volumes of interest (VOI) 
were contoured on the baseline image using an automatic segmentation algorithm, selecting the 
tibia from the tibia/fibula junction to the proximal tibial head. Images were analyzed for bone 
volume fraction relative to total bone volume (BV/TV) and bone mineral density (BMD) using a 
threshold of 600 HU for selecting mineralized bone tissue. Parametric response maps of 
quantitative CT as expressed in Hounsfield units (PRMHU) were generated over the same region 
by first calculating the difference between the Hounsfield units (ΔHU = HUpost-surgery−HUpre-
surgery) for each voxel within the bone pre- and post-surgery. Individual voxels were classified 
based on the extent of change observed in ΔHU. Voxels yielding a ΔHU greater than a pre-
determined threshold were designated red, decreased by more than the threshold were designated 
blue, and otherwise designated green (indicating no significant change from pre-surgery). 
Volume fractions of the total bone were calculated for the three classifications: PRMHU+ (red 
voxels denoting increased HU), PRMHU− (blue voxels denoting decreased HU), and PRMHU0 
(green voxels denoting unchanged HU). The threshold that designates a significant change in HU 
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within a voxel was empirically calculated from one random subject imaged twice on the same 
day, separated by an interval of one hour. Following registration and conversion to HU of the 
two images from the same animal, a linear least squares analysis was performed and the 95% 
confidence interval was determined for use as the PRM threshold, which was set as ± 391 HU. 
Ex vivo image analysis 
Ex vivo images were analyzed at week 4 post-surgery to verify that significant changes in 
bone microenvironment had occurred following ovariectomy in this well-established model of 
osteoporosis relative to sham animals. Images were analyzed using MicroView (GEHC). 
Trabecular VOI were drawn by hand and extrapolated between slices over a 3 mm-long region 
near the proximal tibia. Measures of mean trabecular thickness (Tb.Th), trabecular spacing 
(Tb.Sp), total bone volume (BV), bone volume fraction (BV/TV), mean bone mineral density 
(BMD), and structure model index (SMI) were analyzed. Cortical bone VOI were automatically 
delineated over the bottom four slices from the trabecular VOI. Measures of mean cortical 
thickness, cross-sectional area, and inner and outer perimeters were analyzed. 
Data and statistical analysis 
Data is presented as the mean ± the standard error of the mean (SEM). Differences in 
outcome measures between groups at each time point was determined by a two-tailed, unpaired 
Student's t-test with p < 0.05 denoting significance.  
4.1.3: Results 
Comparison of PRMHU and standard whole-bone analyses  
To assess the effectiveness of the PRM method at identifying bone loss we analyzed 
weekly μCT images using PRM compared to mean BV/TV and BMD between groups. Analysis 
was constrained to tibial bone from proximal tibial plateau distally to tibia/fibula junction 
segmented on the baseline image. The results in Figure 4.1.1 show that BV/TV and BMD were 
significantly different between groups by week 3. In the OVX group, BV/TV decreased by 3.1 ± 
0.6% at the end of the study. BMD decreased by 4.2 ± 1.0% on week 3 but saw no further 





Figure 4.1.1: Plots of relative change in (A) bone volume fraction, BV/TV, and (B) bone 
mineral density, BMD, over the study time period. Quantitative values from registered images 
were determined from a volume-of-interest over the proximal tibial plateau distally to the 
tibia/fibula junction on baseline images. Differences between groups were not seen in either 
BV/TV or BMD until week 3 post-OVX, with decreases of 4.4±1.0% (p=0.002) and 3.4±1.1% 
(p<0.001), respectively, in the OVX group at the end of the study. Data is presented as group 
mean ± SEM. Significant difference between groups was assessed at p<0.05 and indicated by *. 
 
 
Figure 4.1.2: Bar plots showing the volume fraction of (A) increased HU, PRMHU+,  and 
(B) decreased HU, PRMHU-. The OVX group showed a significant increase in PRMHU+ on week 
2 which disappeared at later time points and a progressive increase in PRMHU- until the end of 
the study. For week 1 PRMHU-, group differences were nearly significant, with p=0.08. Data is 
presented as a group mean ± SEM. Significant difference between groups was assessed at p<0.05 





Figure 4.1.3: Representative PRM images from (A) an OVX animal and (B) a sham 
animal, displayed as an axial slice over time (from left to right: weeks 0 to 4, respectively). The 
position of the slice shown is indicated by the yellow box on the surface rendering to the left of 
the PRM results. For each representative animal, (i) grayscale images, (ii) PRM overlays, and (ii) 
PRM scatterplots of individual voxel changes show a decrease in cancellous bone mineral over 
time (blue in the PRM). 
 
Ex vivo μCT measurements of tibial trabecular and cortical bone 
The PRM method, with spatial sensitivity, revealed trabecular bone loss as well as 
cortical expansion in the OVX group. Figure 4.1.2 shows PRM analysis with a representative 
axial slice through the CT image (i–ii) and the scatter plot with pre-surgery HU on the x-axis and 
post-surgery HU at a specific time on the y-axis for the entire VOI (iii) over the study time 
period. The representative slice shown near the proximal tibial plateau was chosen to include 
changes in both trabecular and cortical bone. Trabecular degradation is apparent in the OVX 
animal, PRMHU−, seen as blue in the PRM overlay and scatterplot. Also in the OVX group, 
PRMHU+ (red voxels) indicates a shift in the cortical bone outward, reflecting cortical expansion. 
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These two changes in bone structure are typical of this osteoporosis model [19]. In contrast to the 
OVX animal, the sham animal had very little change in PRM metrics. The few red and blue 
pixels observed were the result of natural bone growth and reflected modeling changes 
associated with skeletal growth. 
 
 
Figure 4.1.4: Representative images of ex vivo images of proximal tibiae four weeks post-
surgery. (A) Surface renderings show regions used for ex vivo analysis (yellow boxes) of 
trabecula (left) and cortex (right).  (B) Maximum intensity projections from a middle slab 
(200m thick) show a clear difference between OVX and Sham animals. (C) Surface renderings 
of OVX (Left) and Sham (Right) trabecular bone (location indicated by yellow box in B) show a 
significant drop in trabecular structure following OVX surgery. (D) Surface rendering of region 
used for cortical analysis, excluding the trabecular region. (E) Parameters obtained from 




Table 4.1.1: ex vivo Trabecular Bone Analysis. 
 
Table 4.1.2: ex vivo Cortical Bone Analysis 
 
The mean volume fractions, PRMHU+ and PRMHU−, from both groups were monitored 
over the study time period (Figure 4.1.3). The PRMHU+ results showed a temporary increase on 
week 2 over control values. This significant difference was lost after week two indicating a 
transient remodeling effect on OVX animals. The PRM map shows that the majority of PRMHU+ 
is along the bone's outer edge, indicating that this increase is due mainly to cortical expansion. 
The subsequent loss of significance between groups is likely normal bone growth in the sham 
group catching up with the remodeling effect in the OVX group. The PRMHU− plot (Figure 
4.1.3B) reflects progressive bone loss which is characteristic of this animal model, with 
significantly higher PRMHU− values observed in OVX than sham animals at all time-points after 
week 1 post-surgery. As shown in Figure 4.1.2, PRMHU− voxels are primarily found in the 
cancellous bone space and indicate loss in trabecular bone mass. The increase is nearly 
significant even at the week 1 imaging time point (p=0.083). By the end of the study, at 4 weeks 
post-surgery, OVX and sham groups resulted in bone loss as measured by PRMHU− of 16.0% (± 
2.3) and 2.5% (± 0.8), respectively (p < 0.001). 
To verify that OVX animals had undergone extensive bone loss following surgery 
relative to sham, we performed ex vivo μCT after 4 weeks on all animals in the study. Images 
were acquired with 18 μm resolution allowing quantification of trabecular structures. Figure 
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4.1.4 illustrates the process of analysis for both trabecula and cortex, with resulting 
measurements. Figure 4.1.4A indicates the location of the trabecular analysis slab (left), region 
for maximum intensity projection (MIP) in B (middle), and slab for cortical analysis (right) as a 
yellow box. Figure 4.1.4B shows representative MIP images for OVX and sham animals, with a 
clearly lower trabecular bone mass in the OVX animal. Figure 4.1.4C shows representative 
isosurfaces for the two groups, taken from the yellow region indicated in B. Figure 4.1.4D shows 
an isosurface of the cortical bone from a representative animal, which was used for cortical 
analysis. Resulting measurements are listed in Figure 4.1.4E, and group means are shown in 
Tables 4.1.1 and 4.1.2 for trabecular bone and cortical bone, respectively. Significant differences 
were seen between groups in all trabecular measurements, indicating degradation of trabecular 
structure. Structural model index (SMI) measurements quantify the extent of rod- or disk-like 
shaping of the trabecular lattice, with higher values indicating more rod-like and lower indicating 
more disk-like shaping. Cortical measurements of average thickness, inner, and outer perimeters 
also showed significant differences between groups. Larger perimeters and decreased cortical 
thickness in the OVX group indicate significant cortical expansion, which is consistent with this 
model. No significant change in cross-sectional area indicates that remodeling occurred without 
significant loss of total cortical bone. 
4.1.4: Discussion 
The goal of this study was to evaluate voxel-based PRM analysis of bone mineral 
changes using in vivo μCT and compare these results to those determined using conventional 
measures of bone mineral density and bone volume. Toward this end we used a well-documented 
model of osteoporosis in rats in which removal of the ovaries initiates bone degradation due to 
hormone deprivation. This animal model has been shown to result in highly-reproducible bone 
loss, characterized by site-dependent decreases in overall bone mass as well as diminished 
trabecular structure and cortical expansion [19, 20]. Clinical osteoporosis is characterized by 
decreases in either bone mineral density (BMD) or bone mineral content (BMC) of over 2.5 
standard deviations below the young adult reference mean (−2.5 T-score), which leads to 
increased fragility and consequently a greater risk of SREs [19]. It is reported that the earliest 
time of statistically detectable cancellous bone loss is approximately 14 days post-OVX in this 
animal model [19, 23]. In this study, PRM showed a near-significant change in PRMHU− by one 
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week post-surgery, which became significant 2 weeks post-OVX, well before any significant 
difference in BMD was detected. In addition to being an early biomarker of bone remodeling, 
PRM also provided locally-resolved spatial information revealing bone degradation and growth 
which was not attainable by BMD measurements.  
Historically, the most utilized method of tracking bone mineral changes in vivo has been 
dual-energy X-ray absorptiometry (DXA). This method, although highly accurate in its 
measurements, is limited in its ability to provide spatial information. The attractiveness of DXA 
in most cases is its measurement accuracy as well as its minimal exposure to ionizing X-rays. 
Doses from quantitative CT imaging can be hundreds of times higher than DXA, but provide 3D 
voxel sizes able to resolve bone micro-structures. Despite the widespread usage of BMD, recent 
studies have indicated that measurement of BMD alone is insufficient for evaluation of bone 
strength [24-27]. Recent studies have explored the use of high resolution CT imaging to model 
bone mechanical characteristics in order to predict fracture risk through finite element analysis 
(FEA) [25, 28-30]. Until recently, mechanical properties of bone were tested ex vivo, requiring 
the use of a large number of animals to provide sufficient data points. Several recent studies have 
shown great accuracy in predicting fractures in femoral and vertebral cases using FEA [29, 31]. 
However very powerful computing hardware is necessary for this technique, especially when 
using nonlinear modeling strategies and the constraints and limitations in application are not yet 
fully understood. Using the spatially resolved bone changes obtained from PRM analysis, 
evaluation of increased fracture risk may be predictable without such rigorous computational 
modeling making this technique more clinically relevant. PRM has the capability of monitoring 
global bone mass changes as well as identification of focal bone loss which would otherwise be 
attenuated in global bone measurements that use summary statistical methods (e.g. mean value 
over a region of interest). For this reason PRM may provide a better foundation for determining 
correctional orthopedic strategies. 
The tradeoff between resolution and imaging time (and therefore radiation dose) is well 
known. For the purposes of this study and its future clinical implications, image resolution was 
sacrificed in order to prioritize low radiation doses, below known tissue response limits [32, 33]. 
Due to the lower resolution of our in vivo measurements, quantification of such trabecular 
parameters as thickness, spacing, and SMI were not feasible. The voxel-wise comparison of HU 
in PRM, however, was able to detect loss in trabecular bone structure as a decrease in HU rather 
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than the loss in binary threshold bone volume that is typically monitored in higher resolution ex 
vivo images. PRM maps are also able to spatially resolve these changes in 3Dspace, allowing for 
focal changes in bone mineral density to be identified and quantified.  
Previous studies have reported results from using a longitudinal voxel-wise comparison 
approach, similar to PRM, to subjectively show spatial changes in bone mass in vivo [34-36]. 
Even though these studies performed voxel-wise comparison, it was used only for qualitative 
presentation and not quantified statistically. Schulte et al. [8] used registered high resolution μCT 
to extrapolate measures of bone formation and resorption rates in the trabecula of mouse 
vertebrae. The study focused primarily on bone histomorphometry and the processes of bone 
adaptation, and would result in high doses of ionizing radiation (IR) to achieve the level of 
resolution necessary, therefore the approach was not designed for clinical application. Since 
PRM compares quantitative Hounsfield units and not binary bone images it is able to detect bone 
structural changes without requiring excessively small resolution (and thus high IR doses). The 
experiments presented here are the first to use PRM to quantify voxel-based changes in bone 
mass in vivo. 
Although PRM was demonstrated here on a model of osteoporosis, PRM analysis may 
have wider clinical applications. Bisphosphonates, used clinically for several years, inhibit the 
resorption of bone by osteoclasts [37]. Interestingly, the degree of fracture risk reduction 
following bisphosphonate therapy is not well explained for by changes in bone mass alone. 
Following 1 year of Risedronate therapy in 2087 individuals, Watts et al. [38] found that fracture 
risk reduction was not dependent on change in BMD, indicating that other factors such as 
remodeling of bone geometry, etc. must play significant roles. PRM analysis may provide a 
sensitive biomarker of bone response to these therapies, leading to prediction of overall outcome 
by direct observation of local sites of anabolic or anti-catabolic effect. Another application of 
PRM is in the assessment of bone response to metastatic cancer [35] where diseases 
characterized by low bone mass and deterioration of microarchitecture often lead to bone 
fragility [5, 19, 39]. Skeletal metastases develop in approximately 70–80% of patients with 
breast or prostate primary cancer, with over 250,000 and 100,000 deaths worldwide each year 
from breast and prostate cancer, respectively [40]. Cancer that has metastasized to the bone may 
present osteolytic, osteoblastic, or a mix of these characteristics. Patients presenting with these 
diseases have a high risk of incurring fractures, resulting in patient pain and increased morbidity. 
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Local changes in bone mass due to metastatic disease can significantly impact the mechanical 
integrity of the skeleton, leading to focal sites of high fracture susceptibility [41]. PRM analysis 
may provide a unique and sensitive measure in differentiating the osteoblastic and osteolytic 
sites which would be highly valuable in strategizing corrective therapy based on local fragility. 
Recent studies have uncovered a close interaction between bone and cancer metastases through 
molecular signaling [42], in which growth of the cancer is highly dependent on the remodeling of 
the surrounding bone. PRMHU analysis may also prove clinically useful in the identification of 
initial forming micro-metastases in the bone and in assessing treatment efficacy for targeted 
therapies that disrupt the molecular signaling between bone and cancer. 
In conclusion, PRM proved highly sensitive in the detection and spatial localization of 
bone mass changes resulting from osteoporosis. Spatial identification of focal sites of bone loss 
over time will provide many new opportunities for clinical application. The voxel-wise analysis 
of registered serial data is a highly flexible tool, and can be applied to a variety of bone disease 
pathologies to provide for detection of spatially varying changes in CT skeletal images over 
time. 
4.2: PRM Detection of Bone Metastasis Response 
4.2.1: Introduction 
Prostate cancer is a leading cause of death in men, with the highest overall incidence rate 
[43] and the majority of fatal cases resulting from metastatic disease. Approximately 90% of 
patients presenting with advanced prostate cancer develop bone lesions [44]. At present there are 
no approved methods for quantifying treatment response in boney metastases. Although 
quantification of systemic plasma levels of prostate-specific antigen (PSA) has shown promise as 
a surrogate biomarker of treatment response, it has not been validated in clinical trials as a 
reliable predictor of patient survival. The high prevalence of this disease and lack of quantitative 
readouts of treatment response highlight the need for new imaging and analysis strategies for the 
evaluation of metastatic bone disease. 
Metastatic bone lesions may affect the surrounding bone by either breaking it down 
(osteolytic) or building/remodeling (osteoblastic), both of which may result in compromised 
bone structure and risk of skeletal-related events. The dependence of metastatic tumor growth on 
its local environment is well documented. Tumor-stroma interaction in the case of bone 
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metastases relies heavily on the release of bone-derived Transforming Growth Factor (TGF-)  
through tumor-initiated bone erosion and remodeling [45]. This interaction has spurred interest 
in developing therapies that treat not only the tumor, but the bone as well. As understanding of 
the cellular mechanisms of this cancer growth, new treatment strategies are continually under 
development. It is also now apparent that assessment of treatment response may benefit greatly 
from evaluation of both soft-tissue tumor changes as well as changes in the tumor micro-
environment. For bone metastases this would mean detecting bone density changes, for which x-
ray CT imaging is well-equipped.  
The PRM method has shown promise in detecting soft-tissue changes after chemotherapy 
in apparent diffusion coefficient (ADC) maps [9-11, 14-16, 46], and more recently in bone 
density changes, as changes in Hounsfield units (HU), in a well-established animal model of 
osteoporosis (Chapter 4.2.1, [47]). The OVX animal model produced predictable systemic bone 
mineral density decreases which were detected very early after ovariectomy by PRMHU. One of 
the great strengths of PRM analysis, however, is its ability to detect localized changes. Most 
bone changes due to metastatic involvement occur at the border of the lesion. PRM analysis, 
applied to CT images of bone metastases, may provide an invaluable tool for assessing localized 
response to treatments targeting the tumor-stromal interaction.  
In this study, PRMHU was evaluated as a biomarker for assessing bone response to 
treatments targeting either the bone (zoledronic acid, ZA) or the tumor (docetaxel). Two prostate 
cancer cell lines, with distinctly different osteolytic/osteoblastic activity, were used to evaluate 
PRM at detecting early bone turnover following metastases and treatment by either ZA or 
docetaxel. The results showed that PRMHU analysis provided early predictive value in assessing 
response to both of these treatments and in both tumor models. A clear distinction between the 
two cell lines was also present, which may provide useful insight into the behavior of an 
individual lesion. PRM results also correlated well with measurements of tumor volume and 
water diffusion changes in the tumor. In conclusion, PRMHU analysis shows a high potential for 








The internal University Committee on Use and Care of Animals (UCUCA) approved the 
experimental protocols used for this study. Before implantation, cells were harvested by 
trypsinization, counted, and re-suspended in serum-free medium for injection. Male severe 
combined immune-deficient (SCID) mice were implanted with intra-tibial injections of or 5x10
5
 
in 10l at about 4-6 weeks of age as previously described (p.64). Animals were maintained 
according to the NIH standards established in the “Guidelines for the Care and Use of 
Laboratory Animals”.  
PC3: Osteolytic Prostate Cancer 
Androgen independent (hormone refractory) human prostate cancer (PC3) cells were 
initiated from a bone metastasis of a grade IV prostatic adenocarcinoma from a 62-year-old male 
Caucasian. PC3 cells were transfected with a luciferase-encoding pLazarus retroviral construct 
using Fugene 6 (Roche Applied Science, Indianapolis, IN) per manufacturer’s instructions.  
LAPC-9: Osteoblastic Prostate Cancer 
LAPC-9 xenografts were derived as previously described [48, 49]. The clinical material 
was propagated as sub-cutaneous xenografts in SCID mice until implantation [50]. 
Treatments 
Zoledronic Acid 
The effect of zoledronic acid (ZA, LKT Laboratories, St. Paul, MN) treatment was 
evaluated on an early-metastasis PC3 tumor model (n=9) and compared to controls (n=4, treated 
with a equivalent volume of PBS). For those mice implanted with PC3, treatment was 
administered subcutaneously in doses of 5mg/kg twice weekly for four treatments, starting three 
days post-implantation, immediately after imaging. 
Docetaxel 
The effect of docetaxel (Taxotere, Sanofi-Aventis, Bridgewater, NJ) was evaluated on the 
LAPC-9 established tumor model (treated: n=3; controls: n=6). Mice were administered a single 
intraperitoneal dose of 20mg/kg in 10% DMSO solution. Treatments were administered starting 
when tumor volumes, as measured by anatomical MRI, reached 7-15mm
3
. For the purposes of 





Imaging of the early-metastasis PC3 animals were imaged on days 0, 3, 7, and then 
weekly post-implant, and LAPC-9 animals were imaged weekly. μCT images were acquired 
using a Siemens Inveon system with the following parameters: 80 kVp, 500 μA, 300-ms 
exposure, 501 projections over 360 degrees, and 49.2-mm field of view (56-μm voxel size). 
MRI 
MRI was performed using a 9.4-T, 12-cm horizontal bore DirectDrive System (Agilent 
Technologies, Palo Alto, CA) with a quadrature mouse head coil (m2m Imaging Corp, 
Cleveland, OH). Images of the tumor-bearing leg were acquired twice weekly starting from the 
day before treatment initiation. Diffusion-weighted images were acquired using a spin-echo 
sequence with navigator echo motion correction and gradient waveforms sensitive to isotropic 
diffusion [51] using the following parameters: repetition time/echo time = 4000/37 ms, field of 
view = 20 × 20 mm, matrix size = 128 × 64, slice thickness = 0.5mm, slice number = 25, and b-
values (diffusion weighting) of 120 and 1200s/mm
2
. Following image acquisition, data that 
included manually drawing volumes of interest on the high diffusion-weighted image to compute 
tumor volumes and diffusion values were stored for analysis. Tumor volumes and apparent 
diffusion coefficient (ADC) values were quantified over time to monitor tumor burden and 
cellularity, respectively.  
Image Analysis 
Volumes-of-interest (VOI) were generated using image thresholding to encompass the 
bone volume (including marrow/trabecular space) surrounding the tumor location, specifically 
the tibia from tibial plateau to tibia/fibular junction. 
Parametric response maps (PRM) were generated by first co-registering post-treatment 
images to corresponding pre-treatment images, and then each image voxel was categorized into 
one of three groups: increase (PRMHU+, red), decrease (PRMHU-, blue), or no significant change 
(PRMHU0, green).  Image co-registration was performed using an automated iterative image 
warping algorithm with a cost function of mutual information (MIAMI Fuse™, University of 
Michigan). A voxel value change was considered significant (red or blue category) if |ΔHU| was 
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greater than 391 HU. This cutoff was pre-determined as the 95% confidence interval for these 
models. 
Statistics 
Significant difference between groups was assessed using an unpaired Student’s t-test 
with p < 0.05, and designated with an asterisk on plots. All data on plots are presented as mean ± 
standard error of the mean (SEM). 
4.2.3: Results 
Treatment with zoledronic acid administered early in the establishment of PC3 intra-tibial 
tumors resulted in bone protection from the tumor’s osteolytic activity and resulting retardation 
of tumor growth (Figure 4.2.1A), with significantly smaller tumors than ZA treatment animals at 
3 weeks post-implantation (p=0.005). Control tumors were un-inhibited in their bone erosion, as 
seen in Figure 4.2.1 B-top and D as progressive increase in PRMHU- (blue). In contrast, animals 
treated with ZA showed a marked increase in bone density as indicated by PRMHU+ (red) (Figure 
4.2.1B-bottom and C) with no significant increase in PRMHU- (Figure 4.2.1D). Surface 
renderings of the tibiae from control animals (Figure 4.2.1B) show the progressive deterioration 
of the bone leading to nearly complete bone destruction in the vicinity of the implant site. Three 
weeks post-implantation, water diffusivity in the tumor, as quantified as ADC, was significantly 
lower in the ZA group than controls (p=0.036), however due to the very small size of the lesions 
and limitations in image resolution this may simply be a partial-volume effect. Although not 
significant at 3 days post-treatment initiation, animals treated with ZA were found to have 
substantially higher bone density than controls as determined by PRMHU+ (p=0.06). A significant 
difference between groups was reached at one week post-treatment initiation. An increase in 
bone density was also observed in the non-tumor-bearing tibiae, with a significant difference 




Figure 4.2.1: PC3 implantations treated with zoledronic acid show a bone-protective 
effect. (A) MRI tumor volume and ADC determined at day 21 post-treatment-initialization 
shows a retardation of tumor growth and significantly lower ADC in the zoledronic acid treated 
animals. (B) Representative images for a control (top) and ZA-treated (bottom) mouse showing 
(from top to bottom) an isosurface, CT slice, PRM overlay, and PRM scatterplot from pre-
treatment to 21 days post-treatment. (C) PRMHU+ bar plot shows significantly higher volume of 
bone that increased in density after treatment compared to controls. (D) PRMHU- bar plot shows 






Figure 4.2.2: LAPC-9 tumors showed a slower mixed PRMHU+/- response with docetaxel 
treatment compared to PC3. (A) Time plots of tumor volume (solid line) and ADC (dashed line) 
show successful response to treatment as volume shrinkage and ADC increase. (B) 
Representative images for a control (top) and docetaxel-treated (bottom) mouse showing (from 
top to bottom) an isosurface, CT slice, PRM overlay, and PRM scatterplot from pre-treatment to 
21 days post-treatment. (C) PRMHU+ bar plot over time shows more bone density increase in the 
docetaxel-treated group compared to controls, significant on days 14 and 21. (D) PRMHU- bar 
plot over time shows very little bone loss in the treated group compared to elevated bone mineral 




Figure 4.2.3: PRMHU plots over time compare un-treated bone changes in PC3 
(diamonds, solid line) to LAPC-9 (squares, dashed line) intra-tibial tumors as quantified by (A) 
PRMHU+ and (B) PRMHU-. Significant difference between groups is denoted by an asterix, *. 
 
Chemotherapy of the established LAPC-9 tumor model resulted in bone normalization 
following tumor therapeutic response (Figure 4.2.2). Tumors were observed to show a 
substantial drop in volume (48 ± 3.7% by week two) and increase in ADC (13 ± 1.2% by week 
two) characteristic of an effective treatment (Figure 4.2.2A). PRMHU analysis (Figure 4.2.2B-D) 
revealed mixed bone remodeling due to the tumor’s known osteolytic and osteoblastic activity, 
with progressive increases in both PRMHU+ and PRMHU- in the control group. Chemotherapeutic 
intervention in this model resulted in higher values in PRMHU+, significant at week 2 (p=0.007), 
and a general decline in PRMHU-. Surface rendering of the tibiae (Figure 4.2.2B) shows 
progressive deformation of the bone in the control group as the tumor grows. In contrast, tibiae 
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from treated animals were found to have re-normalization of the bone structure. No significant 
differences in PRMHU- were found between groups due to the wide variance in the controls. 
PRM results from control (i.e. untreated) animals were also compared between PC3 
(osteolytic) and LAPC-9 (mixed osteolytic/-blastic) tumor models to contrast the different 
phenotypes (Figure 4.2.3). The PC3 tumor model elicited an approximately exponential increase 
in PRMHU- as a result of substantial bone loss, mirroring the expected growth of the tumor (time-
course volume data not obtained). Both PRM readouts for the PC3 model were significantly 
higher than the LAPC-9 model (PRMHU+: p=0.003 at 1 week and p=0.001 at 2 weeks; PRMHU-: 
p<0.001 at 2 weeks).  
4.2.4: Discussion and Conclusions 
The purpose of this study was to evaluate the PRM method on CT images of boney 
metastasis. Two tumor models were evaluated: one highly osteolytic model highlighting early 
establishment of metastases (PC3) with bisphosphonate intervention, and the other a mixed-
phenotype model (LAPC-9) with chemotherapeutic intervention of well-established tumors. Both 
are prostate cancer cell lines, but have greatly differing characteristics. The breast cancer cell line 
previously reported in this manuscript was also considered for comparative analysis; however 
initial analyses were problematic due to the rapid tumor growth fragmenting the bone instead of 
eroding. For this reason, the 1833 model was considered sub-optimal for the purposes of this 
study and was not included. 
The PC3 cell line is well-documented and known to exhibit highly osteolytic behavior. 
Bone erosion, measured by PRMHU-, in untreated lesions exhibited an exponential trend, 
assumed to follow the growth of the tumor. PRMHU+ also showed a significant increase in the 
controls, which may be attributed to a combination of (1) bone healing from the initial cell 
implantation, (2) bone remodeling away from the lesion due to the loss of structural integrity 
around the lesion, (3) the elevated levels of mineral available in the bone environment due to the 
erosion around the lesion, (4) natural bone growth due to the young age of the mice and (5) a 
combination of the above processes. This effect may be mitigated by selecting bone regions only 
in the immediate vicinity of the tumor instead of a fixed length of bone. Treatment with ZA, 
however, had a drastic effect on the bone, increasing bone density throughout the tibia and 
resulting in significantly elevated levels of PRMHU+ over controls and very little PRMHU-. 
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Although this bone-targeted therapy was not able to completely stop tumor growth in this model, 
it did greatly inhibit tumor growth, resulting in smaller lesions after three weeks. Although ADC 
values were significantly diminished in the treated tumors, this difference may have simply been 
a result of partial-volume effects due to the small size of the lesions. PRM analysis was nearly 
able to capture these effects three days post-treatment (PRMHU+, significant at one week). The 
corresponding PRM overlay was also useful in localizing bone changes, with a large region of 
blue apparent (PRMHU-) in the tumor region of control animals compared to the red region in the 
ZA group (PRMHU+) corresponding to healing from the implantation burr hole. 
LAPC-9 tumors are also well-established, but are known to grow much slower than PC3 
tumors and exhibit both osteolytic and osteoblastic behaviors, resulting in more bone remodeling 
than bone loss. This can be seen in the PRM results for the control group (Figure 4.2.2C-D), with 
progressively increasing fractions of both PRMHU+ and PRMHU-. A chemotherapeutic response is 
observed as a decrease in tumor volume and an increase in ADC in the treatment group. In 
addition, an apparent shift in bone remodeling toward PRMHU+ and almost zero PRMHU- is also 
suggestive of a treatment induced response. The high percentage of PRMHU+ and low PRMHU- is 
indicative of a progression from the disorganized state of the bone that resulted from tumor 
involvement back toward the natural stromal structure. The observed elevated values of PRMHU+ 
in the treated group persisted throughout the time course of the study as consequence of the 
already significantly remodeled bone (significant tumor volumes) at baseline that is required for 
MRI analysis. 
In comparing LAPC-9 to PC3 PRMHU results, only data that was acquired without any 
treatment was used (data from treatment groups were included until the first post-treatment time 
point) and day 0 refers to the day of cell implantation. The slower growth of LAPC-9 tumors is 
apparent in the slow and steady increases in both PRMHU+ and PRMHU- compared to PC3. Future 
results may be clarified by the use of older mice whose bones are not still growing and possibly a 
less-damaging tumor implantation method to avoid the natural growth and healing effects present 
in the current study.  
In conclusion, this study presents clear evidence of the utility of PRM analysis for 
detecting bone changes due to varying phenotypes of boney metastasis and their treatment 
strategies. Spatially delineated characterization of bone changes using PRM is able to show 
localized treatment response in order to better understand the mechanisms and side-effects of its 
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actions. PRM methodology may be applied to bone analysis in both clinical patients and pre-
clinical studies to enhance the quantitative readouts of bone change. 
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 Conclusions Chapter 5:
Accuracy in the diagnostic interpretation of radiological images is dependent upon many 
variables and resulting image quality. Conventional image characteristics such as voxel size and 
gray scale bit depth are important factors, but significant improvements in diagnosis will likely 
rely on post-processing methods aimed toward facilitating the delineation of radiological 
findings, improving both the confidence and accuracy of the interpreter. The overarching goal of 
this research effort was to advance the development of non-invasive imaging biomarkers through 
appropriate and optimized techniques. This research effort explored the improvement of 
quantitative readout sensitivity for assessment of treatment efficacy through complementary 
multimodal imaging platforms. While region-specific histogram analysis was used, this research 
effort also explored the value of voxel-by-voxel analysis of changes in imaging readouts over 
time as a more sensitive and accurate approach for delineation of disease-related and treatment-
associated changes in the tissue of interest. Thus the proper selection of image modalities and 
post-processing techniques is most likely to significantly advance radiological practice and 
improve overall patient care. 
In my search for novel imaging biomarkers of therapeutic efficacy, I investigated the 
value in DW-MRI acquisition of extended b-values and non-linear parametric models for 
improved sensitivity and interpretation. For assessment of cancer chemotherapeutic response in 
this study, high b-value diffusion models did in fact provide a better fit to the attenuation curve 
observed in living tissue. However, my results also showed that these higher-order models did 
not necessarily provide additional information, and in fact were much less stable and required 
significantly greater imaging and post-processing time. The main, or “fast”, diffusion parameters 
all had similar sensitivity to response, but the standard mono-exponential model was found to be 
much less sensitive to noise. Thus, after careful evaluation of the possible acquisition variables 
involved with the generation of DW-MR images, it was found that due to the simplicity of its 
104 
 
analytical calculation and faster acquisition time, use of a limited number of lower b-values are 
overall more appropriate for routine clinical use.  
An additional aspect of my research effort was to investigate the use of combined 
imaging metrics from multi-modal readouts. In this regard, assessment of targeted anti-vascular 
response was undertaken utilizing DW- along with DCE-MRI. My results revealed the role of 
each modality and their relative contributions in predicting cancer response to this class of 
agents. Although there was a clear and strong response in vascular-sensitive imaging readouts 
(DCE-MRI), there was no increase in tumor ADC values which would be expected if a drop in 
tumor cellularity occurred. In fact, I observed a significant drop in ADC which was attributed to 
a decrease in tumor edema, secondary to the drug-induced decrease in neovascular leakiness. 
Thus the use of multi-modal approaches for assessment of anti-vascular treatment effects was 
shown to more fully characterize the responses of the tumor in which transient growth control 
occurred but without appreciable mortality of tumor cells. 
Imaging not only allows observations to be made on the tumor itself, but also on the host 
tissue which is important, as tumor-host interactions are well known to occur in cancer biology. 
The interactions between metastatic lesions and their micro-environment are a complex 
phenomenon which can progress to tumor propagation and infiltration into the local stroma. 
Current therapy research is aimed at disrupting this interaction, resulting in re-normalization of 
the microenvironment as well as tumor cell kill. In this context, a multi-modality imaging 
approach was explored for characterization of tumor-stromal response to standard therapies in a 
mouse model of boney metastasis. Image analysis allowed for exploration of the overall balance 
and dynamics between osteolytic and osteoblastic activity during tumor growth and therapeutic 
interventions. It was found that the complementary use of clinically-applicable and pre-clinical 
optical imaging readouts was able to provide a more comprehensive understanding of tumor-
local response to both bone-protective and tumor-targeted therapies. These findings present 
opportunities for improvement in clinical evaluation of therapeutic response as well as our 
understanding of the interconnected signaling pathways associated with tumor-stromal 
interactions using non-invasive imaging. 
Additionally, the development of improved image post-processing algorithms was 
undertaken through evaluation of a novel voxel-based analytical method termed the parametric 
response map (PRM). When applied to CT imaging, this method was shown to be sensitive in the 
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detection and quantification of spatially-varying alterations in mineral density using preclinical 
models of osteoporosis and bone metastasis. More detailed studies were also undertaken to 
evaluate the capabilities of this imaging approach for distinguishing osteolytic from osteoblastic 
phenotypes of bone metastasis in an effort to identify unique biomarker signatures for each. 
These studies demonstrated that PRM provided the capability for non-invasive detection of 
important tumor characteristics as well local bone response to interventions designed to reduce 
the process of bone erosion. These research findings are an important contribution toward 
providing new image-based diagnostic capabilities which can provide additional information to 
assist with clinical decision-making for patients with high risk of incurring skeletal related 
events. 
In conclusion, there is a strong need for optimization of imaging protocols in order to 
provide for improved diagnostic medicine as well as treatment response sensitivity. This research 
effort identified several key areas for optimizing radiological contributions towards improved 
patient management: 
• Optimized acquisition of images 
• Improvements in image post-processing 
• Multimodal image combinations to enhance diagnosis 
• Voxel-by-voxel, PRM-based analysis of images 
Overall, quantitative imaging is linked to physiological mechanisms through simplified 
mathematical models. Care must be taken in model selection to ensure accuracy and robustness 
of quantitative readouts as well as sensitivity to a physiological change. Also, multi-modal 
imaging is critical for forming a comprehensive understanding of tumor treatment response that 
can be used to inform pharmaceutical development as well as clinical care. Cancer is a highly 
complex disease, changing its micro-environment in order to thrive. Assessment of tumor and 
stromal treatment effects is critical for improved understanding of the underlying biological 
processes involved, which are needed to make progress in the treatment of this disease. The work 
presented here signifies a push toward the development and clinical implementation of new non-




Appendix A: Calculation of Local Model Sensitivity 
Model sensitivity to individual input parameters was calculated as the partial derivative 
of the signal-intensity equation with respect to each parameter. Sensitivity was assessed at static 
values of all input parameters and a fixed range of b-values or times (for diffusion or 
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Permeability: 
i. * denotes the convolution operator 
ii. Using the chain rule,  
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a. Apostrophe, ‘, indicates the derivative of the function 
b.  ( )                   ( )                 
c.  ( )              ( )            
d. Rss = R1(0) 
e. Sss = S(0) 
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